# Vinyl glycyl amino beta lactam derivatives.

## Abstract
beta Lactam antibiotics are disclosed having the partial structure CHEM where R 1 is CHEM in which R 2 , R 3 and R 4 are the same or different and each is hydrogen halogen optionally substituted C1 6 alkyl optionally substituted C3 7 cycloalkyl optionally substituted C2 6 alkenyl optionally substituted C2 6 alkynyl amido cyano carboxy formyl C1 6 alkoxycarbonyl mono or di C1 6 alkylamido C1 6 alkylcarbonyl an aryl group a heterocyclyl group or R 3 and R 4 are joined together to form the residue of a carbocyclic ring having a total of from 3 to 7 carbon atoms in the ring or R 3 and R 4 are joined together to form the residue of a heterocyclic ring in which R 3 and R 4 together may be represented by the formula CH2 mX CH2 n in which X is oxygen, sulphur or a group NR 5 wherein R 5 is hydrogen, acyl, an amino protecting group, or C1 6 alkyl, m is 1 to 3 and n is 1 to 3 and also the use thereof. Processes for the preparation of the compounds are disclosed together with intermediates for use therein.

## Claims
Claims 1. A compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof EMI90.1 wherein R1 represents a group EMI90.2 in which R2,R3 and R4 are the same or different and each is hydrogen halogen optionally substituted C1 6 alkyl optionally substituted C37 cycloalkyl optionally substituted C26 alkenyl optionally substituted C26 alkynyl amido cyano carboxy formyl C1 6 alkoxycarbonyl mono or di C16 alkylamido C1 6 alkylcarbonyl an aryl group a heterocyclyl group or R3 and R4 are joined together to form the residue of a carbocyclic ring having a total of from 3 to 7 carbon atoms in the ring or and R4 are joined together to form the residue of a heterocyclic ring in which R3 and R4 together may be represented by the formula CH2 mX CH2 n in which X is oxygen, sulphur or a group NR5 wherein R5 is hydrogen, acyl, an amino protecting group, or C16 alkyl, m is 1 to 3 and n is 1 to 3 and Y is EMI91.1 wherein R17 is hydrogen or C1 6 alkyl R18 and R19 may be the same or different each being C26 alkyl p is an integer having the value 0, 1 or 2t yl is oxygen, sulphur, SO, S02, or CH2 and Z represents hydrogen, halogen or an organic group such as C1 4 alkoxy, CH2Q or CH CH Q wherein Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carbamoyloxy, carboxylic ester, C14 alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via nitrogen with the proviso that when Y is S C CH3 2 and R2 is methyl, R3 cannot be hydrogen when R4 is phenyl and R3 cannot be phenyl when R4 is hydrogen. 2. A compound as claimed in Claim 1 in which Y is S C CH3 2 or S CH2 CZ . 3. A compound as claimed in Claim 1 or Claim 2 in which Y is S C CH3 2 . 4. A compound as claimed in any one of claims 1 3 in which R2 is hydrogen or C1 6 alkyl and R3 and R4 are the same or different and each is halogen, C16 alkyl or together form a carbocyclic ring containing 5 or 6 carbon atoms. 5. A compound as claimed in claim 3 in which R2 is hydrogen and R3 and R4 are the same or different and each is halogen or C16 alkyl. 6. A compound as claimed in claim 3 in which R2 is hydrogen and R3 and R4 together form a carbocyclic ring containing 5 or 6 carbon atoms. 7. A compound as claimed in any one of claims 1 to 6 selected from the following or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof 6ss D 2 Aminobut 3 enamido penicillanic acid 6ss D 2 Amino 3 phenylbut 3 enamido penicillanic acid 613 D 2 Amino 4, 4 dichlorobut 3 enamido penicillanic acid 6ss D 2 Amino 3 methylbut 3 enamido penicillanic acid 7ss D 2 Amino 3 methylbut 3 enamido cephalosporanic acid 713 ED 2 Amino 3 methylbut 3 enamido 3 desacetoxy cephalosporanic acid 6p D 2 Amino 3 ethylbut 3 enamido penicillanic acid 6ss D 2 Amino 3 methylpent 3 E enamido penicillanic acid 6ss D 2 Amino pent 3 E enamido penicillanic acid 6ss D 2 Amino 3 methylhex 3 E ,5 dienamido penicillanic acid 6ss D 2 Aminohex 3 E enamido penicillanic acid 6ss D 2 4 cyclohexylbut 3 E enamido penicillanic acid 6ss D 2 Amino 4 phenylbut 3 E enamido penicillanic acid 6ss D,L 2 Amino 4 4 chlorophenyxl but 3 E enamido penicillanic acid 6,ss D 2 Amino 3 trifluoromethylbut 3 enamido penicillanic acid 6ss D 2 Amino 3 thien 2 ylbut 3 enamido penicillanic acid 6ss D,L 2 Amino 4 chloro 3 thien 2 ylbut 3 Z enamido penicillanic acid 6B D, L 2 Amino 4 chloro 3 thien 2 ylbut 3 E enamido penicillanic acid 66 D 2 Amino 4 chloro 3 methylbut 3 E enamido penicillanic acid 66 D,L 2 Amino 4 chloro 3 methylbut 3 Z enamido penicillanic acid 6n 5 Acetoxy D 2 aminopent 3 E enamido penicillanic acid 6p D 2 Amino 3 cyclohexylidenepropanamido penicillanic acid 6n D,L 2 Amino 4 methoxy 3 methylenebutanamido penicillanic acid 6n D 2 Amino 4 methylpent 3 enamido penicillanic acid 8. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 7 together with a pharmaceutically acceptable carrier or excipient. 9. A pharmaceutical composition as claimed in claim 8 which further comprises a 5 lactamase inhibitor. 10. A process for the preparation of a compound as claimed in Claim 1 which process comprises reacting a compound of formula III EMI94.1 wherein the amino group is optionally substituted with a group which permits acylation to take place, and Rx is hydrogen or a carboxyl blocking group, with anN acylating compound formed from a salt or N protected derivative of an amino acid of formula IV EMI95.1 wherein R1 and are as defined with respect to formula I above and any reactive groups may be protected and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking groups RX ii removing any protecting groups elsewhere in in the molecule iii converting the product into a salt or in vivo hydrolysable derivative thereof. 11. A compound as claimed in claim 1, which compound is the in vivo hydrolysable derivative of formula Ia or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI96.1 wherein R1, and Y are as defined with respect to formula I and R7 and R8 are the same or different and each is hydrogen or C16 alkyl. 12. A compound of the formula IVA EMI96.2 wherein R1 is defined with respect to formula I and R is hydrogen, C1 6 alkyl, C2 6 alkenyl, C3 7 cycloalkyl or aryl C1 6 alkyl. 13. A process for the preparation of a compound of formula IV EMI96.3 wherein R1 is defined with respect to formula I which process comprises treating a compound of the formula IVA EMI97.1 wherein R1 is as hereinbefore defined and R is hydrogen, C16 alkyl, C2 6 alkenyl, C3 7 cycloalkyl or aryl C1 6 alkyl with a reducing agent capable of converting the groupEMI97.2 whilst leaving the remainder of the molecule unaffected. 14. A process for the preparation of a compound of the formula IVB or a salt or in vivo hydroxysable derivative thereof EMI97.3 which process comprises a reacting a compound of the formula EMI98.1 wherein Ar is aryl, R2 is defined as in claim 1, R is as defined in claim 12, and Rx is a carboxyl blocking group with a compound of the formula EMI98.2 wherein R3 and R4 are as defined in claim 1 or b reacting a compound of the formula EMI98.3 wherein R, R2, and RX are as hereinbefore defined andR20 is C16 alkyl with a compound of the formula EMI99.1 wherein R3 and R4 are as defined in claim 1 or c reacting a compound of the formula EMI99.2 wherein Ar, R3 and R4 are as hereinbefore defined with a compound of the formula EMI99.3 wherein R, R2 and RX are as hereinbefore defined and, if necessary, after any of the processes a , b or c above, carrying out one or more of the following steps i removing the carboxyl protecting group Rx ii converting the product into a salt or in vivo hydrolysable derivative thereof. 15. The use of a compound of formula I as defined inClaim 1 or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof for the manufacture of a medicament for therapeutic purposes.

## Description
NOVEL COMPOUNDSThis invention relates to a class of p lactam derivatives which have antibacterial activity and are of value in the treatment of infections in animals1 including mammals and especially humans. In particular the invention relates to a class of p lactam derivatives with an acyl group in the side chain derived from vinyl glycine or a substituted derivative thereof. The invention also relates to a process for the preparation of such compounds, and to pharmaceutical compositions comprising them.The present invention provides a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof EMI1.1 wherein R1 represents a group EMI1.2 in which R21R3 and R4 are the same or different and each is hydrogen halogen optionally substituted C1 6 alkyl optionally substituted C3 7 cycloalkyl optionally substituted C26 alkenyl optionally substituted C26 alkynyl amido cyano carboxy formyl C1 6 alkoxycarbonyl mono or di C16 alkylamido C1 6 alkylcarbonyl an aryl group a heterocyclyl group or R3 and R4 are joined together to form the residue of a carbocyclic ring having a total of from 3 to 7 carbon atoms in the ring or R3 and R4 are joined together to form the residue of a heterocyclic ring in which R3 and R4 together may be represented by the formula CH2 mX CH2 n in which X is oxygen, sulphur or a group NR5 wherein R5 is hydrogen, acyl, an amino protecting group, or C1 6 alkyl, m is 1 to 3 and n is 1 to 3 and Y is EMI2.1 wherein R17 is hydrogen or C1 6 alkyl R18 and R19 may be the same or different each being C26 alkyl p is an integer having the value 0, 1 or 2 yl is oxygen, sulphur, SO, SO2, or CH2 and Z represents hydrogen, halogen or an organic group such as C14 alkoxy, CH2Q or CH CH Q wherein Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carbamoyloxy, carboxylic ester, C14 alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via nitrogen with the proviso that when Y is S C CH3 2 and R2 is methyl, R3 cannot be hydrogen when R4 is phenyl and R3 cannot be phenyl when R4 is hydrogen.Suitably Y is S C CH3 2 , S CH2 , S CH2 C dH2Q or O CH2 C CH2O Preferred values for Y in the compounds of formula I are S C CH3 2 and S CH2 C CH2Q , i.e. the compound of formula I is a derivative of a penicillin or cephalosporin.A particularly preferred value for Y is S C CH3 2 .Substituents that may be present on those groups R2, R3 and R4 defined hereinabove as being optionally substituted include halogen, carboxy, C1 6 alkoxycarbonyl, carbamoyl, aryl, heterocyclyl, hydroxy,C1 6 alkanoyloxy, cyano, amino, C16 alkanoylamino, mono or di C1 6 alkylamino, aryl C1 6 alkylthio,C1 6 alkoxy, or C37 cycloalkyl.When used herein the term aryl includes phenyl and naphthyl optionally substituted with up to five fluorine, chlorine, C1 6 alkyl, C1 6 alkoxy, halo C1 6 alkyl, yhdroxy, amino, carboxy, C1 6 alkoxycarbonyl, or C16 alkoxycarbonyl C16 alkyl groups. The term heterocyclyl herein denotes single or fused aromatic or non aromatic heterocyclic rings linked via a carbon atom to the rest of the molecule, said rings containing up to four hetero atoms selected from oxygen, nitrogen and sulphur and being optionally substituted with up to three halogen, C16 alkyl, C16 alkoxy, halo C1 6 alkyl, hydroxy, amino, carboxy, C1 6 alkoxycarbonyl, C1 6 alkoxycarbonyl C1 6 alkyl, aryl or oxo groups. Suitably the heterocyclic ring comprises from 4 to 7 ring atoms, preferably 5 or 6 atoms. Depending on the nature of the heterocyclyl group, certain compounds within formula I may occur in two or more tautomeric forms these are included within the scope of the present invention.The term halogen refers to fluorine, chlorine, bromine and iodine.As used herein the term acyl denotes C16 alkylcarbonyl, arylcarbonyl or aryl C1 6 alkylcarbonyl.As used herein, the term amino protecting group denotes a group attached to nitrogen which may be readily cleaved to give a free amino group NH2 or NH .Such groups and conditions for their cleavage are well known in the art see, for example, Protective groups in Organic Synthesis by T.W. Greene John Wiley andSons, 1981 . Examples of suitable amino protecting groups include benzyloxycarbonyl optionally substituted in the phenyl ring by one or two substituents selected from C14 alkyl, C14 alkoxy, trifluoromethyl, halogen or nitro C14 alkoxycarbonyl, for example tert butoxycarbonyl or C14 alkyloxycarbonyl optionally substituted in the alkyl group by up to three substituents chosen from C14 alkoxy, halo or nitro, for example 2,2,2, trichloroethoxycarbonyl or l chloroethoxycarbonyl.As used herein the term carboxylic acid ester includes C16 alkyl, C26 alkenyl, and aryl C16 alkyl esters, and esters which may readily be cleaved such as in vivo hydrolysable ester groups as hereinbelow defined and other ester groups noted hereinbelow as being removable under conventional conditions.The carbon atom marked in formula I is asymmetric and the compound may be derived from the side chain having a D, L or DL configuration at that position.All forms of compound I are included in this invention. Suitably, the carbon atom marked is derived from the D configuration and compounds with that configuration are referred to herein asD stereoisomers.The term in vivo hydrolysable derivative encompasses in vivo hydrolysable esters and other pro drugs of the compound of formula I .Examples of suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt. Suitable ester groups of this type include those of part formula i , ii and iii EMI5.1 EMI6.1 wherein Ra is hydrogen, methyl, or phenyl, Rb is C16 alkyl, C16 alkoxy or phenyl or Ra and Rb together form a 1,2 phenylene group optionally substituted by one or two methoxy groups Rc represents C1 6 alkylene optionally substituted with a methyl or ethyl group Rd and Re independently represent C16 alkyl Rf represents C16 alkyl. Examples of suitable in vivo hydrolysable ester group include for example acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, a acetoxyethyl and a pivaloyloxyethyl groups alkoxycarbonyloxyalkyl groups, such as ethoxycaronyloxymethyl and alpha ethoxycarbonyloxyethyl dialkylaminoalkyl especially di loweralkylamino alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl lactone groups such as phthalidyl and dimethoxyphthalidyl the group of formula EMI6.2 wherein R6 is hydrogen, C1 6 alkyl or phenyl and esters linked to a second p lactam antibiotic or to a p lactamase inhibitor.As will readily be appreciated by those skilled in the art the compound of the invention of formula I contain both an amino group and a CONH moiety in the side chain and will therefore form cyclic derivatives on reaction with aldehydes such as formaldehyde or ketones such as acetone . Such cyclic derivatives are further examples of in vivo hydrolysable derivatives or pro drugs of the compounds of formula I .Thus, in another aspect of the present invention, there is provided a pro drug of a compound of formula I having the formula Ia or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI7.1 wherein R1, and Y are as defined for formula I above and R7 and R8 are the same or different and each is hydrogen or C16 alkyl. Preferred compounds within formula Ia include those in which R7 and R8 are both hydrogen or both methyl.The compounds of the present invention contain both an amino group and a carboxyl group and may, therefore, exist as the zwitterion or may form salts with suitable acids or bases. Suitable pharmaceutically acceptable salts of the compounds of formula I or Ia include metal salts, eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tri 2 hydroxyethyl amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N benzyl p phenethylamine, dehydroabietylamine, N, N bisdehydroabietylamine, ethylenediamine, or bases of the pyridine type such as pyridine, collidine or quinoline.Suitable acid addition salts of compound I or Ia include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane sulphate, a keto glutarate, a glycerophosphate, and glucose l phosphate.Preferably the acid addition salt is a hemisuccinate, hydrochloride, a ketoglutarate, a glycerophosphate or glucose l phosphate, in particular the hydrochloride salt.Salts within formula I or Ia may be prepared by salt exchange in conventional manner, for example a solution of the lithium salt in water may be passed through a bed of ion exchange resin in the sodium form eg Amberlite IR 120 a sodium salt of a sulphonated polystyrene divinyl benzene co polymer in about ten fold excess until elution is complete the resulting sodium salt may be obtained by freeze drying or the like. Similarly a sodium salt may be converted to a lithium salt or to a potassium salt in similar manner. N.B. Amberlite is a trade name .Suitable C16 alkyl groups for R2, R3 and R4 may be straight or branched chain and include methyl, ethyl, n or iso propyl, n , sec , iso or tert butyl. In those cases where the C16 alkyl group carries a substituent the preferred C16 alkyl groups for R2, R3 and R4 include methyl, ethyl and n propyl.Suitable C37 cycloalkyl groups for R2, R3 and R4 include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.Suitable C26 alkenyl groups for R2, R3 and R4 include ethenyl, propenyl and butenyl.Suitable C26 alkynyl groups for R2, R3 and R4 include ethynyl, propynyl and butynyl.Suitably when R3 and R4 are joined together to form a carbocyclic ring, the carbocyclic ring contains a total of 3,4, 5 or 6 carbon atoms in the ring. The carbocyclic ring may be fully saturated or may contain up to two conjugated or non conjugated double bonds.Suitably when R3 and R4 are joined together to form a heterocyclic ring one of the integers n and m has the value of 2.Preferably n and m are both 2.Suitable aryl groups for R2, R3 and R4 include phenyl, optionally mono or di substituted by C1 6 alkyl, hydroxy, C16 alkoxy, trifluoromethyl, chlorine or fluorine.Suitable heterocyclyl groups for R2, R3 and R4 include 2 thienyl, 3 thienyl, 2 furyl and 3 furyl.More suitably R2 is hydrogen, methyl, ethyl, hydroxymethyl, methoxymethyl, phenyl or 2 thienyl.More suitably R3 is hydrogen, methyl, acetoxymethyl, ethyl, vinyl, cyclohexyl, 4 chlorophenyl, phenyl, or chloro.More suitably R4 is hydrogen, methyl, or chloro.One preferred subgroup within the present invention provides a compound of formula II or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI10.1 wherein R2, R3, R4 and are as hereinbefore defined.Preferred groups for R2 include hydrogen, phenyl, methyl and ethyl.Preferred groups for R3 and R4 include hydrogen, ethyl, and chlorine. In one preferred aspect of the invention, R2, R3 and R4 are all hydrogen.In a particularly preferred aspect of the invention, R2 is hydrogen and R3 and R4 are both chlorine.In another particularly preferred aspect of the invention R3 is ethyl and R2 and R4 are both hydrogen.In yet a further particularly preferred aspect of the invention R2 is hydrogen and R3 and R4 together form a carbocylic ring having a total of 6 carbon atoms.Since the lactam antibiotic compounds of the present invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 50 pure, more suitably at least 75 pure and preferably at least 95 pure are on a wt wt basis . Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions. Although the purity of intermediate compounds of the present invention is less critical it will readily be understood that the substantially pure form is preferred as for the p lactam antibiotic compounds. Preferably, whenever possible, the compounds of the present invention are obtained in crystalline form. Some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be formed. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation. Suitable values for Q in the compounds of the formula I or Ia include the acetoxy, heterocyclylthio group, and nitrogen containing heterocyclic group bonded via nitrogen.When the group Z as hereinbefore defined is CH CH Q, preferred values of Q include methyl and 4 methyl 1,3thiazol 5 yl.The heterocyclylthio group may suitably be represented by the formula S Het wherein Het is a five or six membered heterocyclic ring containing from 1 to 4 atoms selected from N, O, and S unsubstituted or substituted with one or two groups selected from C16 alkyl, C16 alkoxy, aminoalkyl, hydroxyalkyl, C16 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylalkyl, trifluoromethyl, hydroxy, halogen, oxo, mono and di C16 alkylaminoalkyl, and carboxyalkyl or two substituents may be linked to form the residue of a heterocyclic or carbocyclic ring.Examples of the group Het include unsubstituted and substituted imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, oxazolyl, triazinyl and oxadiazolyl.Suitable groups Het include unsubstituted and substituted 1, 2, 3 triazolyl 1, 2, 4 triazolyl tetrazolyl oxazolyl thiazolyl 1, 3, 4 oxadiazolyl 1, 3, 4 thiadiazolyl, or 1, 2, 4 thiadiazolyl.The heterocyclylthio group may thus be, for example, l methyl lH tetrazol 5 ylthio, 2 methyl 1,3,4 thia diazol 5 ylthio, l carboxymethyl lH tetrazol 5 ylthio or 6 hydroxy 2 methyl 5 oxo 2H 1,2,4 triazin 3 ylthio.A preferred heterocyclylthio group when the group Z as hereinbefore defined is CH2Q is 1,2,3 triazol 4 ylthio of structure EMI13.1 The nitrogen containing heterocyclic group bonded via nitrogen is suitably an optionally substituted pyridinium group suitably the pyridinium group is substituted with one or two groups selected from C16 alkyl, C16 alkoxy, hydroxyalkyl, C16 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylmethyl, carbamoyl, trifluoromethyl, hydroxy, halogen, oxo, and aminoalkyl.More suitably, the nitrogen containing heterocyclic group bonded via nitrogen may be an optionally substituted tetrazolyl group, particularly 5 methyltetrazol 2 yl of structure EMI13.2 Specific compounds within the invention include the following or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof 6ss D 2 Aminobut 3 enamido penicillanic acid 6ss D 2 Amino 3 phenylbut 3enamido penicillanic acid 6ss D 2 Amino4,4 dichlorbut 3 enamido penicillanic acid 6j3 D 2 Amino 3 methylbut 3 enamido penicillanic acid 7ss D 2 Amino 3 methylbut 3 enamido cephalosporanic acid 713 D 2 Amino 3 methylbut 3 enamido 3 desacetoxy cephalosporanic acid 6ss D 2 Amino 3 ethylbut 3 enamido penicillanic acid 6ss D 2 Amino 3 methylpent 3 E enamido penicillanic acid 6ss D 2Amino pent 3 E enamido penicillanic acid 613 D 2 Amino 3 methylhex 3 E , 5 dienamido penicillanic acid 6ss D 2 Aminohex 3 E enamido penicillanic acid 6ss D 2 Amino 4 cyclohexylbut 3 E enamido penicillanic acid 6ss D 2 Amino 4 phenylbut 3 E enamido penicillanic acid 6ss D,L 2 Amino 4 4 chlorophenyl but 3 E enamido penicillanic acid 6,ss D 2 Amino 3 trifluoromethyl 3 enamido penicillanic acid 6ss D 2 Amino 3 thien 2 ylbut 3 enamido penicillanic acid 6ss D,L 2 Amino 4 chloro 3 thien 2 ylbut 3 Z enamido penicillanic acid 6B D,L 2 Amino 4 chloro 3 thien 2 ylbut 3 E enamido penicillanic acid 6ss D 2 Amino 4 chloro 3 methylbut 3 E enamido penicillanic acid 6 3 D,L 2 Amino 4 chloro 3 methylbut 3 Z enamido penicillanic acid 6ss 5 Acetoxy D 2 aminopent 3 E enamido penicillanic acid 6ss D 2 Amino 3 cyclohexylidenepropanamido penicillanic acid 6p D,L 2 Amino 4 methoxy 3 methylenebutanamido penicillanic acid 613 D 2 Amino 4 methylpent 3 enamido penicillanic acid The compounds of formula I may be prepared by reacting a compound of formula III EMI16.1 wherein the amino group is optionally substituted with a group which permits acylation to take place, and Rx is hydrogen or a carboxyl blocking group, with anN acylating compound formed from a salt or N protected derivative of an amino acid of formula IV EMI16.2 wherein R1 and are as defined with respect to formula I above and any reactive groups may be protected and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking groups RX ii removing any protecting groups elsewhere in in the molecule iii converting the product into a salt or in vivo hydrolysable derivative thereof.The in vivo hydrolysable derivatives pro drugs of formula Ia may be prepared by conventional methodology, i.e. reacting a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with an aldehyde or ketone of the formula EMI17.1 wherein R7 and R8 are as hereinbefore defined.The compounds of formula I or Ia with the preferredD side chain stereochemistry may be separated from a mixture of diastereoisomers of formula I or Ia by conventional methods or prepared from amino acids of formula IV that have the D configuration.The amino group in the amino acid of formula IV is generally protected by a removable blocking group before the reactive N acylating derivative is formed.Alternatively, the amino group in the amino acid IV may be protected by the prior formation of an acid addition salt, for example the hydrochloride.Suitable groups which permit acylation to take place and which are optionally present on the amino group of the starting material of the formula III includeN silyl, N stannyl and N phosphorus groups, for example trialkylsilyl groups such as trimethylsilyl, trialkyltin groups such as tri n butyltin, groups of formula P.R9R10 wherein R9 is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, R10 is the same as R9 or is halogen or R9 andR10 together form a ring suitable such phosphorus groups being P oC2H5 2 P C2HS 2, EMI18.1 Suitable amino blocking groups which may be used to block the amino group in IV are those amino protecting groups well known in the art which may be removed under conventional conditions without disruption of the remainder of the molecule. Particularly suitable examples of amino protecting groups which may be employed in derivatives of IV in which the amino group is blocked include 2,2,2 trichloroethyloxycarbonyl and 3 methoxyearbonylprop 2 en 2 yl. Suitable carboxyl blocking derivatives for the group C02Rx in formula III include salts and ester derivatives of the carboxylic acid. The derivative is preferably one which may readily be cleaved at a later stage of the reaction. Suitable salts include metal salts, such as those with sodium, potassium and lithium, and tertiary amine salts, such as those with trilower alkylamines, N ethylpiperidine, 2,6 lutidine, pyridine, N methylpyrrolidine, dimethylpiperazine. A preferred salt is with triethylamine. Suitable ester forming carboxyl blocking groups aret those which may be removed under conventional conditions. Such groups for Rx include benzyl, p methoxybenzyl, 2,4, 6 trimethylbenzyl, 3,5 di t butyl 4 hydroxy benzyl, benzoylmethyl, p nitrobenzyl, 4 pyridylmethyl, 2, 2,2 trichloroethyl, 2,2, 2 tribromoethyl, t butyl, t amyl, diphenylmethyl, triphenylmethyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofuran 2 yl, tetrahydropyran 2 yl, pentachlorophenyl, p toluenesulphonylethyl, methoxymethyl, a silyl, stannyl or phosphorus containing group, such as described above, an oxime radical of formula N CHR11 where R11 is aryl or heterocyclic, or an in vivo hydrolysable ester radical such as defined above.The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular Rx group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, or by hydrogenation under conditions wherein other parts of the molecule are unaffected.A reactive N acylating derivative of a salt orN protected derivative of the amino acid IV is employed in the above process. The choice of reactive derivative will of course be influenced by the chemical nature of the substituents of the acid.Suitable N acylating derivatives of salts orN protected derivatives of the acid IV include acid halides, preferably the acid chloride or bromide.Acylation with an acid halide may be affected in the presence of an acid binding agent for example, tertiary amine such as triethylamine or dimethylaniline , an inorganic base such as calcium carbonate or sodium bicarbonate or an oxirane, which binds hydrogen halide liberated in the acylation reaction. The oxirane is preferably a C1,6 1,2,alkylene oxide such as ethylene oxide or propylene oxide. The acylation reaction using an acid halide may.be carried out at a temperature in the range 500C to 500C, preferably 200C to 200C, in aqueous or non aqueous media such as aqueous acetone, aqueous tetrahydrofuran, ethyl acetate, dimethylacetamide, dimethyl formamide, acetonitrile, dichloromethane, 1, 2 dichloroethane, or mixtures thereof.Alternatively, the reaction may be carried out in an unstable emulsion of water immiscible solvent, especially an aliphatic ester or ketone, such as methyl isobutyl ketone or butyl acetate.The acid halide may be prepared by reacting salts orN protected derivatives of the amino acid IV with a halogenating eg chlorinating or brominating agent such as phosphorus pentachloride, thionyl chloride or oxalyl chloride.Alternatively, the N acylating derivative of the salt or N protected derivative of the amino acid IV may be a symmetrical or mixed anhydride. Suitable mixed anhydrides are alkoxyformic anhydrides, or anhydrides with, for example, carbonic acid monoesters, trimethyl acetic acid, thioacetic acid, diphenylacetic acid, benzoic acid, phosphorus acids such as phosphoric or phosphorous acids or aliphatic or aromatic sulphonic acids such as p toluenesulphonic acid . The reaction may be carried out in the presence of an organic base such as triethylamine.Alternative N acylating derivatives of salts orN protected derivatives of acid IV are the acid azide, or activated esters such as esters with 2 mercaptopyridine, cyanomethanol, p nitrophenol, 2,4 dinitrophenol, thiophenol, halophenols, including pentachlorophenol, monomethoxyphenol, N hydroxy succinimide, N hydroxy benzotriazole, or 8 hydroxyquinoline or amides such as N acylsaccharins or N acylphthalimides or an alkylidene iminoester prepared by reaction of the acid IV with an oxime.Other reactive N acylating derivatives of salts orN protected derivatives of the acid IV include the reactive intermediates formed by reaction in situ with a condensing agent such as a carbodiimide, for example,N,N diethyl , di n propyl or diisopropylcarbodiimide, N,N di cyclohexyl carbodiimide, or N ethyl N 3 dimethylaminopropylcarbodiimide a suitable carbonyl compound, for example, N,N carbonyldiimidazole or N,N carbonylditriazole an isoxazolinium salt, for example, N ethyl5 phenylisoxazolinium 3 sulphonate or N t butyl 5methylisoxazolinium perchlorate or an N alkoxycarbonyl 2 alkoxy 1,2 dihydroquinoline, such as N ethoxycarbonyl 2 ethoxy 1,2 dihydroquinoline. Other condensing agents include Lewis acids or a phosphoric acid condensing agent such as diethylphosphorylcyanide.The condensation reaction is preferably carried out in an organic reaction medium, for example, dichloromethane, dimethyl formamide, acetonitrile, alcohol, benzene, dioxan or tetrahydrofuran.Compounds of formula IV may be prepared by treating compounds of formula IVA or salts and esters thereof EMI22.1 wherein R1 is as hereinbefore defined and R is hydrogen, C1 6 alkyl, C26 alkenyl, C37 cycloalkyl or aryl C1 6 alkyl with a reducing agent which leaves the remainder of the molecule substantially unaffected and thereafter, if necessary, converting the product into the free acid. Suitable reducing agents include, for example, zinc in the presence of formic acid, and other reagents known in the art to be capable of converting oximes or oximino ethers into amines.Compounds of the formula IVA are novel and form another aspect of the present invention.It will be appreciated that compounds of the formula IVA may possess either syn or anti stereochemistry.Both syn and anti stereoisomers and mixtures of the two stereoisomers in any proportion are encompassed within the present invention.Preferably the group R in compounds of the formula IVA is methyl.According to the invention there is also provided a process for the preparation of a compound of formula IV from a compound of formula IVA by the method hereinabove described. The compound of formula IVA may also be written as IVB EMI23.1 wherein R, R2, R3 and R4 are as hereinbefore defined.Compounds of formula IVB may be prepared by a variety of methods, for example via the Wittig or modifiedWittig reactions shown in the general Scheme below in which R, R2, R3 and R4 are as hereinbefore defined, RX is a readily removable carboxylic acid blocking group which may be removed at the end of the synthesis,Ar is an aryl group as hereinabove defined and R20 is C1 6 alkyl. SchemeEMI24.1 Details of the conditions and reagents used to effect the transformations shown in the Scheme above may be found in the Examples given hereinbelow.Preferably the group Ar is phenyl and R20 is C1 4 alkyl especially methyl. Compounds of the formula IV may also be prepared by deprotecting an N protected derivative of a compound of formula IV .Useful intermediates of this type are those of formula IVC EMI25.1 wherein R2, R3, R4 and Rx are as hereinbefore defined which may be converted into compounds of formula IV by treatment with aqueous mineral acid, for example 5N hydrochloric acid and thereafter, if necessary, removing the group RX. Compounds of formula IVC may be prepared by reaction of the appropriately substituted 2 oxazoline with activated zinc dust in a suitable solvent such as tetrahydrofuran, by a method analogous to that described by F.Heinzer and D.Bellus, Helv. Chem. Acta., 1981, 64, 2279.The sub group of compounds within the present invention of formula V EMI25.2 wherein Y11 Het , R1, and Rx are as defined hereinbefore may suitably be prepared by reacting a compound of formula VI EMI26.1 wherein ylt R1, Rx and are as hereinbefore defined and wherein any reactive groups may be protected andR12 is a leaving group with a thiol of formula Het SHSuitable leaving groups R12 include halogen such as iodide or bromide, acyloxy groups such as, for example, the acetoxy group, or aryl or C1 6 alkylsulphonyloxy groups such as p toluenesulphonyloxy or methanesulphonyloxy.The thiol HetSH may be reacted as the free compound or a salt with an alkali metal such as sodium or potassium. This reaction is desirably conducted in a solvent. For example, use can be made of water, or organic solvents inert to the starting compounds, such as dimethylformamide, dimethylacetamide, dioxane, acetone, alcohol, 1,2 dichloroethane, acetonitrile, dimethylsulfoxide or tetrahydrofuran, or mixtures thereof. The reaction temperature and time depend, among other factors, upon the starting compounds and solvent to be employed but generally the reaction is carried out at a selected temperature within the range of 0 to 1000C for a selected time of a few hours to several days. The reaction is desirably conducted between pH 3 and 7.To prevent oxidation of the thio compounds it is advantageous to carry out the reaction in an inert gaseous atmosphere, e.g. nitrogen gas.The subgroup of compounds within the present invention of formula VII .EMI27.1 wherein R1, ylw Rx and are as defined hereinbefore and R13 is an optionally substituted pyridinum group may suitably be prepared by reacting a compound of formula VI as hereinbefore defined with the appropriately substituted pyridine.Suitably the reaction with the pyridine is carried out in a polar solvent such as water, and in the presence of a catalyst such as an alkali metal thiocyanate or an alkali metal halide such as, for example sodium iodide.The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof together with a pharmaceutical carrier or excipient.The composition may be formulated for administration by any route, such as oral, topical or parenteral.Administration by the oral route is generally preferred. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.Tablets and capsules for administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine, tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica disintegrants, for example potato starch or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia non aqueous vehicles which may include edible oils , for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol preservatives, for example methyl or propyl p hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride.For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water remdved under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parental suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The composition may contain from 0.1 to 99.5 by weight, preferably from 10 60 by weight, of the active material, depending on the method of administration.Where the compositions comprise dosage units, each unit will preferably contain from 50 500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 mg to 20 g per day for an average adult patient 70 kg. , for instance 1500 mg per day, depending on the route and frequency of administration. Such dosages correspond to approximately 1.5 to 285 mg kg per day. Suitably the dosage is from 0.25g to 6g per day.The daily dosage is suitably given by administering a compound of the invention several times in a 24 hour period. Typically, 250 mg. is administered 2 or 3 times a day although, in practice, the dosage and frequency of administration which will be most suitable for an individual patient will vary with the age, weight and response of the patients, and there will be occasions when the physician will choose a higher or lower dosage and a different frequency of administration. Such dosage regimens are within the scope of this invention.No toxicological effects are indicated when a compound of the invention of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof is administered in the above mentioned dosage range.The compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a p lactamase inhibitor may be employed. Advantageously, the compositions also comprise a compound of formula VIII or a pharmaceutically acceptable salt or ester thereof EMI31.1 wherein A is hydroxyl substituted hydroxyl thiol a group of formula S02R14 wherein R14 is C1 6 alkyl substituted thiolt amino mono or di hydrocarbylsubstituted amino mono or di acylamino an optionally substituted triazolyl group or an optionally substituted tetrazolyl group as described in EP 0 053 893.Suitable substituents A in formula VIII include hydroxyl, tetrazol l yl and tetrazol 2 yl.A further advantageous composition comprises a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof together with a compound of formula IX or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI31.2 wherein B is hydrogen, halogen or a group of formula EMI32.1 in which R15 and R16 are the same or different and each is hydrogen, C16 alkoxycarbonyl, or carboxy or a pharmaceutically acceptable salt thereof.Further suitable p lactamase inhibitors include 6 alkylidene penems as described in European PatentApplication No. 81301683.9 Publication Number 0 041 768 .Further suitable p lactamase inhibitors include 613bromopenicillanic acid and salts and in vivo hydrolysable esters thereof and iodo penicillanic acid and salts and in vivo hydrolysable esters thereof.Compositions of this invention comprising a lactamase inhibitor are formulated in a conventional manner.The present invention also provides a method of treating bacterial infections in animals, in particular humans or domestic mammals, which comprises the administration of a composition of this invention. The preferred method of administration is via the oral route.The antibiotic compounds of the present invention are active against a wide range of Gram positive organisms including B. subtilis S. aureus such as, for example Oxford B. catarrhalis S. faecalis I S. pyogenes CN10 H. influenzae E. coli and P. mirabilis.A particular feature of the compounds of the present invention of formula I and pharmaceutically acceptable salts and in vivo hydrolysable derivatives thereof is their excellent absorption as shown in animal species following oral administration.The excellent absorption properties of these compounds may also be demonstrated by measuring the AbsorptionIndex that is the ratio of urine recoveries from oral p.o. and subcutaneous s.c. administration in animal species which is generally as good as, and in some cases much better than, that of well known antibacterial agents such as amoxycillin.The following Examples illustrate the preparation and biological activity of the compounds of the present invention.The following abbreviations are used Abbreviation Full NameDMF Dimethylformamide 6 APA 6n Aminopenicillanic acidTHF Tetrahydrofuran 7 ACA 7p Aminocephalosporanic acid 7 ADCA 7n Amino 3 desacetoxycephalosporanic acidNOE Nuclear Overhauser Effect EXAMPLE 1 a. Potassium D 2 3 methoxycarbonylprop 2 en 2ylamino but 3 enoateMethyl acetoacetate 0.61m1, 5.6mmol and D 2 aminobut3 enoic acid 0.515g, 5.1mmol in 0.87M potassium hydroxide in methanol 6.2 ml, 5.35mmol were heated under reflux for 40 minutes and evaporated to dryness in vacuo.Toluene 10ml and ethanol 5m1 were added to the residue then reevaporated and the residue triturated with ether to give the title compound 1.140g, 86 9max KBr 1645, 1610, 1565, 1500, 1436, 1369, 1269, 1159, 925 and 784cm 1 H 250MHz, DMSO d6 1.77 3H, s, , 3.47 3H, s , 4.17 1H, dd, JH2, NH 6.6Hz, JH2, H34.7Hz , 4.25 1H, s , 4.8 5.0 2H, m , 5.95 6.15 1H, m , and 9.10 1H, d,JNH, H26.6Hz .b. 6ss D 2 Aminobut 3 enamido penicillanic acidPotassium D 2 3 methoxycarbonylprop 2 en 2ylamino but 3 enoate 0.474g, 2mmol in acetone 8ml was cooled to 200C then N methylmorpholine 2p1 and ethyl chloro formate 192pl were added and the mixture stirred at 20 i 50C for 40 minutes. A solution of 6ss amino penicillanic acid 0.48g, 2.2mmol and triethylamine 320 l in acetone 8ml and water 16m1 was added and the solution stirred for one hour without cooling. Acetone was removed in vacuo and the aqueous residue maintained at pH1 with 5N hydrochloric acid for 20 minutes, washed with ether 2 x 25m1 , adjusted to pH 4.7 and freeze dried 1.24g . Chromatography on HP20SS eluting with water afforded the title compound 0.104g, 17 max KBr 1767, 1695, 1591, 1534, 1393, 1388, 1255 and 1122cm 1 H 250MHz, D2O 1,53 3H, s , 1.64 3H, s , 4.26 1H, s , 4.69 1H, d, J 7.5Hz , 5.54 1H, d, J 3.8Hz , 5.58 1H, d, J 3.8Hz , 5.6 5.7 2H, m , and 5.9 6.1 1H, m . Mass spectrum ve ion glycerol H2O MH 300 .EXAMPLE 2 a. D 2 2,2,2 Trichloroethoxycarbonyloxylamino but 3 enoic acid 2,2,2 Trichloroethyl chloroformate 0.56ml, 4.lmmol in acetone 10ml was added dropwise to D 2 aminobut 3enoic acid 0.373g, 3.7mmol in water 20ml and acetone lOml maintained at pH 9.8 i 0.2 with 2.5NNaOH. The solution was then stirred for 30 minutes, concentrated in vacuo, washed with ether 2x30ml , acidified to pH2 and extracted with chloroform 4x25ml .The extracts were washed with water 2x50ml , dried and evaporated to provide the title compound as a crystalline solid, recrystallised from ethyl acetate cyclohexane 0.741g, 73 , mp. 141 1420C alpha D20 3.16 c 1, EtOH 60MHz, CD3 2CO 4.72 2H, s , 4.7 5.1 1H, m , 5.1 5.5 2H, m , 5.7 6.3 lH,m , 7.05 lH,d, JNH, H 37Hz , and 9.41 1H, br s .b. Sodium 6ss D 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillanateA suspension of D 2 2,2,2 trichloroethoxycarbonylamino but 3 enoic acid 0.639g, 2.5mmol in dichloromethane 20ml was treated with oxalyl chloride 0.5ml and DMF 5 l and stirred until a clear solution was obtained, ca. hour. The solvent was removed in vacuo and the acid chloride, max CH2C12 1800, 1750 and 1502cm 1, in acetone lOml added to 6 APA 0.648g, 3mmol and triethylamine 85 l in water 20ml and acetone 10ml .After the solution had been stirred for one hour it was concentrated in vacuo, washed with ether 2x25ml , acidified to pH2.5 and extracted with chloroform 4 x 25ml . The extracts were washed with water 2 x 50ml , dried and evaporated to a foam 1.099g . This in ether 20ml was treated with 2N sodium 2 ethyl hexanoate in 4 methylpentan 2 one 1.16ml , diluted with light petroleum, bp. 60 800C, 20ml and the precipitated sodium salt collected and dried in vacuo 0.996g, 80 .c. 6ss D 2 Aminobut 3 eanmido penicillanic acidFreshly activated zinc dust 1.5g was added to sodium 6ss D 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillanate 0.776g in 0.25M potassium dihydrogen phosphate 16ml and THF 4ml and the mixture maintained at pH5 with 40 orthophosphoric acid. After 10 minutes a further portion of activated zinc 1.5g was added and stirring continued for 10 minutes when reverse phase hplc showed no remaining starting material. The zinc was filtered off, filtrate washed with ether 2 x 25ml , concentrated in vacuo and chromatographed on HP20SS eluting with water.Fractions containing the product were bulked, reduced to ca 2ml, diluted with n propanol 4ml and left to crystallise at OOC. The crystalline dihydrate was collected and dried in vacuo 0.171g, 33 Found C,43.22 H,6.02 N,12.44 S,9.868. C12H17N304S. 2H2O requires C,42.97M H6.31 N,12.53 S,9.56 ir and nmr spectra as in example ib. EXAMPLE 3 6ss D 2 Aminobut 3 eanmido penicillanic acidHydrogen chloride gas was bubbled throughD 2 aminobut 3 enoic acid hydrochloride 0.138g, immol in methanol free dichloromethane 5ml for 30 minutes. The mixture was cooled in an ice bath and freshly sublimed phosphorous pentachloride 0.21g, 1.005mmol in dichloromethane 3ml added. After 30 minutes the suspension was evaporated to dryness, toluene 5ml added, reevaporated and the residue triturated with anhydrous ether.This acid chloride hydrochloride was suspended in dichloromethane 5ml , cooled to 300C and treated with N,O bistrimethylsilyl 6 APA from 6 APA, 0.216g, immol in dichloromethane 10ml . The mixture was stirred without cooling, for two hours then extracted with water 2 x 10ml . The aqueous extract was adjusted to pH 4.8 and freeze dried 0.600g . Chromatography on HP2OSS followed by preparative reverse phase hplc provided material identical with that described in example ib. Preparation 1 a. Methyl D 2 benzyloxycarbobylamino but 3 enoateN Benzyloxycarbonyl D glutamic acid 5 methyl ester 3.65g., 12.4mmol and cupric acetate monohydrate 0.62g, 3.lmmol in toluene 75ml were stirred under argon at 200C for hour. Acetic acid free lead tetra acetate 11.05g, 24.8mmol was added and the mixture stirred vigorously and heated at 1000C for 3 hours. The cooled solution was diluted with ethyl acetate 75ml , filtered through celite, washed with water 2 x 50ml and saturated sodium hydrogen carbonate solution 2 x 50ml , dried and evaporated to an oil 3.174g .Flash chromatography eluting with 10 ethyl acetate in hexane afforded the title compound, 0.974g, 32 H 60MHz, CDCl3 3.65 3H, s , 4.7 5.05 1H, m , 5.08 2H, s , 5.1 5.5 2H, m , 5.5 5.7 1H, m , 5.6 6.2 3H, m , and 7.27 5H, s .b. D 2 Aminobut 3 enoic acid hydrochlorideMethyl D 2 benzyloxycarbonylamino but 3 enoate 2.30g in 6N hydrochloric acid 45ml was heated under reflux for one hour, cooled, washed with chloroform 2 x 25ml and evaporated to dryness. The crystalline residue was triturated with hot acetone to give the title compound, 1.058g, 838 , mp 168 1700C dec. a 20D 63.640 c 1.9, H20 sH 250MHz, D20 4.60 1H, d, J 7Hz , 5.5 5.65 2H, m , and 5.9 6.1 1H, m .c. D 2 Aminobut 3 enoic acidPropylene oxide 1.35ml was added to a stirred solution of the hydrochloride 0.929g in methanol 4ml . After two hours more methanol 4ml was added, the solid collected, washed with methanol 2ml and dried in vacuo 0.562g, 82 , mp 218 2220C dec. alpha D20 79.05 c 1, H2O Found C, 47.32 H, 6.84 N, 13.64 . C4H7N02 requires C, 47.52, H, 6.98 N, 13.85 . Example 4 a. D,L 3 Phenyl 2 2,2,2 trichloroethoxyearbonylamino but 3 enoic acidD,L 2 Amino 3 phenylbut 3 enoic acid 0.514g, 2.9mmol, F. Heinzer and D. Bellus, Helv. Chim. Acta., 1981,64, 2279 was converted to the title compound as described in example 2a 0.650g, 63 mp 103 1050C from ethyl acetate cyclohexane Found C, 44.27 H, 3.38 N, 4.02 C1, 30.14 . C13H12C13N04 requires C, 44.28 H, 3.43 N, 3.97 Cl, 30.16 H 60MHz, CD3 2CO 4.73 2H, s , 5.32 1H, d, J 8Hz , 5.42 and 5.52 2H, 2s , 6.60 1H, br s , 6.73 1H, d, J 8Hz , and 7.0 7.6 5H, m .b. Sodium 6ss D,L 3 phenyl 2 2,2,2 trichloroethoxy carbonylamino but 3 enamido penicillanatePrepared as described in example 2b 78 .c. 6ss 2 Amino 3 phenylbut 3 enamido penicillanic acidsDeprotection of sodium 6ss D,L 3 phenyl 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillinate 0.43g was performed as described in example 2c. Chromatography of the crude product onHP20SS eluting with 4 THF in water provided 6ss L 2 Amino 3 phenylbut 3 enamido penicillanic acid 50mg, 17 9max KBr 1769, 1676, 1602, 1512, 1397 and 1318cm 1 dH 250MHz, D2O 1.45 3H, s , 1.46 3H, s , 4.17 1H, s , 4.93 1H, s , 5.40 1H, d, J 4Hz , 5.53 1H, d, J 4Hz , 5.54 and 5.65 2H, 2s , and 7.43 5H, s followed by a mixture of D and L stereoisomers 73mg, 25 , then 613 D 2 amino 3 phenylbut 3 enamido penicillanic acid 35mg, 12 9max KBr 1767, 1675, 1603, 1511, 1398 and 1318cm 1 SH 250MHz, D20 1.42 3H, s ,l.51 3H, s , 4.14 1H, s , 4.72 1H, s , 5.3 5.4 2H, m , 5.46 and 5.55 2H, 2s , and 7.41 5H, s . Mass spectrum ve ion thioglycerol MH 376 , MNa 398 . EXAMPLE 5 a. D,L 4,4 Dichloro 2 2,2,2 trichloroethoxycarbonylamino but 3 enoic acidD,L 2 Amino 4,4 dichlorobut 3 enoic acid hydrochloride 2.07g, lOmmol was treated with 2,2,2 trichloroethyl chloroformate 1.5ml, llmmol at pH9.25 i 0.25, using the method described in example 2a, to provide the title compound 1.623g, 47 , mp 155 1560C from ethyl acetate cyclohexane OH 60MHz, CD3 2CO 4.81 2H, s , 5.16 1H, dd, JH 2,H 3 9Hz, JH 2, N H 8Hz , 6.22 1H, d, JH 3,H 2 9Hz , 7.16 1H, d, JNH, H 2 8Hz , and 9.65 1H, br s .b. Sodium 6ss D,L 4,4 dichloro 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillanatePrepared using the method described in example 2b 52 SH 60MHz, CD3 2CO 1.53 3H, s , 1.63 3H, s , 4.27 1H, s , 4.67 2H, s , 4.7 5.2 1H, m , 5.2 5.5 2H, m , 6.00 1H, d, J 9Hz , 7.0 7.7 2H, m , and 8.85 1H, br s .c. 6p 2 Amino 4,4 dichlorobut 3 enamido penicillanic acidsDeprotection of sodium 6ss D,L 4,4 dichloro 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillinate 0.725g as described in example 2c and chromatography on HP20SS eluting with 1 then 2 THF in waterprovided 6ss L 2 amino 4,4, dichlorbut 3enamido penicillanic acid 55mg, 11 max KBr 1766, 1675, 1608, 1507, 1397 and 1320cm 1 H 250MHz, D20 1.50 3H, s , 1.61 3H, s , 4.24 1H, s , 4.44 1H, d, J 9Hz , 5.43 1H, d, J 4Hz , 5.57 1H, d, J 4Hz , and 6.07 1H, d, J 9Hz followed by a mixture ofD and L stereoisomers 51mg, 11 then 6ss D 2 amino 4,4 dichlorobut 3 enamido penicillanic acid 45mg, 98 9max KBr 1770, 1690, 1615, 1520, 1396 and 1320cm 1 6H 250MHz, D20 1.50 3H, s 1.60 3H, s , 4.27 1H, s , 4.98 1H, d, J 10Hz , 5.46 1H, d, J 4Hz , 5.56 1H, d, J 4Hz , and 6.22 1H, d, J 10Hz , Mass spectrum ve ion thioglycerol MH 368 , MNa 390 .EXAMPLE 6 a. D 3 Methyl 2 2,2,2 trichloroethoxyearbonylamino but 3 enoic acidD 2 Amino 3 methylbut 3 enoic acid 2.630g, 17.3mmol,J.E. Baldwin, S.B.Haber, C. Hoskins and L.I. Kruse,J. Org. Chem., 1977,42, 1239, S. Uyeo and H. Ona,Chem. Pharm. Bull., 1980,28, 1563 was converted to the title compound as described in example 2a 3.452g, 69 , m.p. 95 990C from cyclohexane dH 60MHz, CD3 2CO 1.87 3H, d, Jl 2Hz , 4.82 2H, 8 , 4.8 5.3 3H, m , 7.0 1H, br 5 , and 10.5 1H, s .b. Sodium 6,P D 3 methyl 2 2,2,2 trichloroethoxy carbonylamino but 3 enamido penicillanatePrepared as described in example 2b 88 .c. 6,ss D 2 Amino 3 methylbut 3 enamido penicillanicacidDeprotection of sodium 6,ss D 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillinate was performed as described in example 2c. Chromatography of the crude product on HP20SS, eluting with 0.66 1.25 THF in water, provided the title compound 50 Vmax KBr 2971, 1771, 1686, 1599, 1520, 1389 and 1315cm 1 H 250MHz, D2O 1.48 3H, s , 1.60 3H, s , 1.80 3H, 8 , 4.22 1H, 8 , 4.64 1H, s , 5.33 and 5.34 2H, 2s ,5.51 1H, d, J 4Hz , and 5.54 1H, d, J 4Hz . EMass spectrum ve ion thioglycerol MH 314 , 2M H 627 .EXAMPLE 7 1. Sodium 7,ss D 3 methyl 2 2,2,2 trichloroethoxy carbonylamino but 3 enamido cephalosporanatePrepared as described in example 2b, using 7 ACA instead of 6 APA 37 .b. 7,ss D 2 Amino 3 methylbut 3 enamido cepahlaosporanic acidDeprotection of sodium 7ss D 3 methyl 2 2,2,2 tri chloroethoxycarbonylamino but 3 enamido cephalosporanate was performed as described in example 2c. Chromatography of the crude product on HP20SS, eluting with 1i 2hZ THF in water, provided the title compound 33 9max KBr 1770, 1693, 1602, 1387, 1340 and 1234cm l dH 250MHz, D20 1.81 3H, s , 3.35 and 3.63 2H, 2d, J 18Hz , 4.64 1H, s , 4.65 4.86 2H, 2d, under HOD , 5.15 1H, d, J 4.7Hz , 5.35 2H, m , and 5.73 1H, d, J 4.7Hz . EMass spectrum ve ion thioglycerol MH AcOH 310 , MH 370 , 2M H 739 . EXAMPLE 8 a. Sodium 7,ss D 3 methyl 2 2,2,2 trichloroethoxy cabonylamino but 3 enamido 3 desacetoxycephalosporanatePrepared as described in example 2b, using 7 ADCA instead of 6 APA 47 . b. 7,ss D Amino 3 emthylbut 3 enamido 3 dexacetoxy cephalosporanic acidDeprotection of sodium 7,ss D 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido 3deacetoxycephalosporanate was performed as described in example 2c. Chromatography of the crude product on HP2OSS, eluting with 1h 2 THF in water, provided the title compound 50 vial KBr 3403, 2976, 1757, 1688, 1584 and 1359cm l dH 250MHz, D20 1.80 3H, s , 1.87 3H, s , 3.18 and 3.56 2H, 2d, J 18Hz , 4.57 1H, s , 5.08 1H, d, J 4.5Hz , 5.30 2H, br s , and 5.62 1H, d, J 4.5Hz . EMass spectrum ve ion thioglycerol MH 312 , 2M H 623 , 3M H 936 .EXAMPLE 9 a. D,L 3 Ethyl 2 2,2,2 trichloroethoxycarbonylamino but 3 enoic acidD,L 2 Amino 3 ethylbut 3 enoic acid hydrochloride 260mg, 1.57mmol, F. Heinzer and D. Bellus, Helv.Chim. Acta., 1981,64, 2279 was converted to the title compound as described in example 2a, 320mg, 67 dH 60MHz, CD3 2CO 1.09 3H, t, J 7Hz , 2.25 2H, q, J 7Hz , 4.80 2H, s , 4.85 5.3 3H, m , 6.95 1H, br d , and 9.82 1H, s .b. Sodium 6ss D,L 3 ethyl 2 2,2,2 trichloroethoxy carbonylamino but 3 enamido penicillanatePrepared as described in example 2b 78 .c. 6,ss 2 Amino 3 ethylbut 3 enamido penicillanic acidsDeprotection of sodium 6ss D,L 3 ethyl 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillinate 417mg was performed as described in example 2c. Chromatography of the crude product on HP20SS, eluting with 0.75 1 THF in water provided 6,ss L 2 amino 3 ethylbut 3 enamido penicillanic acid 95mg, 36 9max KBr 2968, 1771, 1686, 1600, 1516, 1394 and 1316cm 1 H 250MHz, D2O 1.06 3H, t, J 7.3Hz , 1.50 3H, s , 1.57 3H, s , 2.08 2H, m , 4.25 1H, s , 4.68 1H, s , 5.37 1H, s , 5.40 1H, s , 5.46 1H, d, J 4.0Hz , and 5.58 lH, d, J 4.0Hz . Mass spectrum ve ion thioglycerol MH 328 followed by a mixture of D and L stereoisomers 47mg, 18 then 6,13 D 2 amino 3 ethylbut 3 enamido penicillanic acid 20mg, 7.6 max KBr 2968, 1767, 1688, 1597, 1395 and 1320cm 1 H 250MHz, D20 1.07 3H, t, J 7.3Hz , 1.48 3H, s , 1.60 3H, s , 2.06 2H, m , 4.21 1H, s , 4.64 1H, s , 5.35 1H, s , 5.37 1H, s , and 5.52 2H, m . EMass spectrum ve ion thioglycerol MH 328 ,MH thioglycerol 436 , 2M H 655 Example 10 a. D,L 3 Methyl 2 2,2,2 trichloroethoxycarbonylamino pent 3 E enoic acidD,L 2 Amino 3 methylpent 3 E enoic acid hydrochloride 1.36g, 8.2mmo1 for preparation see F. Heinzer andD. Bellus, Helv. Chim.Acta, 1981, 64, 2279 was converted to the title compound as described in Example 2a 1.62g, 65 , m.p. 133 1370C chloroform cyclohexane Found C, 35.90 H, 4.09 N, 4.61 C1 34.70 . C9H12Cl3NO4 requires C, 35.49 H, 3.97 N, 4.60 C1, 34.92 OH 250MHz, CD3 2CO 1.64 3H, d,J 6.8Hz , 1.71 3H, s , 4.73 1H, d, J 7.9Hz , 4.79 2H, s , 5.68 1H, q, J 6.5Hz , 7.12 1H, br d , and 11.1 1H, br s , some of the Z isomer of the title compound, E Z ratio 8 1, was also present 6H inter alia 5.32 d, J 7.8Hz . Mass spectrum ve ion ammonia MH 304 , MNH 4 321 .b. 613 D,L 3 Methyl 2 2,2,2 trichloroethoxy carbonylamino pent 3 E enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 79 .c. 6p 2 Amino 3 methylpent 3 E enamido penicillanic acidsDeprotection of 6p D,L 3 methyl 2 2,2,2 trichloro ethoxycarbonylamino pent 3 E enamido penicillanic acid 1.58g was performed as described in Example 2c.Chromatography of the crude product on HP20SS, eluting with 0.5 0.8 THF in water, provided 6p L 2 amino 3 methylpent 3 E enamido penicillanic acid 179mg, 17 9max KBr 2969, 1771, 1688, 1602, 1515, 1388 and 1316cm l dH 250MHz, D20 1.49 3H, s , 1.55 3H, s , 1.64 3H, s , 1.69 3H, d, J 6.6Hz , 4.25 1H, s 4.62 1H, s , 5.44 1H, d, J 3.9Hz , 5.59 1H, d, J 3.9Hz , and 5.95 1H, br q, J 6.6Hz . EMass spectrum ve ion thioglycerol MH 328 followed by a mixture of Dand L stereoisomers 354mg, 34 then 6ss D 2 amino 3 methylpent 3 E enamido penicillanic acid lllmg, 11 max KBr 2970, 1767, 1684, 1599, 1522, 1390, and 1318cm 1 6H 250MHz, D20 1.49 3H, s , 1.59 3H, s , 1.65 3H, s , 1.69 3H, d, J 6.9Hz , 4.22 1H, s , 4.56 1H, s , 5.50 1H, d, J 3.9Hz , 5.54 1H, d, J 3.9Hz and 5.91 1H, br q . EMass spectrum ve ion thioglycerol MH 328 .Example 11 a. D,L 2 2,2,2 trichloroethoxycarbonylamino pent3 E enoic acid D, L 2 Amino pent 3 E enoic acid hydrochloride 1. 97g crude for preparation see W.J. Greenlee, J.Org.Chem., 1984, 49, 2632 was converted to the title compound as described in Example 2a 0.534g , m.p. 139 1400C Found C, 33.33 H, 3.38 N, 4.86 C1, 36.17 . C8H10C13NO4 requires C, 33.07 H, 3.47 N, 4.82 C1 36.61 H 250MHz, CD3 2CO 1.72 3H, m , 4.77 1H, m , 4.81 2H, ABq, J 12.1Hz , 5.65 1H, m , 5.91 1H, m , and 7.19 1H, d, J 7Hz on irradiating at 61.7 the signal at 65.65 collapsed to a double doublet J 15.3 and 6.9Hz and the signal at 65.91 collapsed to a double doublet J 15.3 and 0.9Hz , confirming the E configuration.b. 6ss D,L 2 2,2,2 trichloroethoxycarbonylamino amino pent 3 E enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt quantitative . c. 6ss 2 Amino pent 3 E enamido penicillanic acidsDeprotection of 6ss D,L 2 2,2,2 trichloroethoxycarbonylamino pent 3 E enamido penicillanic acid 690mg, 1.7mmo1 was performed as described in Example 2c. Chromatography of the crude product on HP20SS, eluting with 0.5 18 THF in water, provided 6ss L 2 amino pent 3 E enamido penicillanic acid 105mg, 20 smax KBr 2971, 1766, 1683, 1596, 1520, 1395 and 1317cm 1 H 250MHz, D20 1.54 3H, s , 1.63 3H, s , 1.80 3H, d, J 6.3Hz , 4.29 1H, s , 4.63 1H, d, J 8.3Hz , 5.5 5.7 3H, m , and 6.19 1H, m . Mass spectrum ve ion thioglycerol MH 314 followed by a mixture of D and L stereoisomers 106mg, 20 then 6ss D 2 aminopent 3 E enamido penicillanic acid 129mg, 24 9max KBr 3411, 2969, 1764, 1683, 1602, 1394 and 1318cm 1 sH 250MHz, D20 1.54 3H, 8 , 1.64 3H, s , 1.81 3H, dd, J 6.4 and 1.4Hz , 4.27 1H, s , 4.63 1H, d, J 8.5Hz , 5.5 5.7 3H, m , and 6.18 1H, m .Example 12 a. Ethyl 2 methoxyimino 3 methyl hex 3 E ,5 dienoateAllyl triphenylphosphonium bromide 9.582g, 25mmol was suspended in dry ether 150ml and treated slowly with n butyllithium 1.6M, 15.6m1, 25mmol at ca. 50C. The mixture was stirred at room temperature for 2.5h, then ethyl 2 methoxyimino 3 oxo butanoate 4.325g, 25mmol in dry ether lOOml was added slowly and the mixture stirred for 3h. After filtering, the solution was washed with saturated ammonium chloride 100ml and brine lOOml , dried and evaporated to give a red oily solid 3.48g .Flash chromatography on silica gel, using 0 5 ethyl acetate in cyclohexane as eluant, gave a colourless oil 1.24g, 25 OH 60MHz, CDCl3 1.32 3H, t, J 7Hz , 1.96 3H, s , 3.92 3H, s , 4.38 2H, q, J 7Hz , and 5.2 5.6 and 6.0 7.2 4H, 2m .b. Ethyl 2 amino 3 methyl hx 3 E ,5 dienoateEthyl 2 methoxyimino 3 methyl hx 3 E ,5 dienoate 1.23g, 6.2mmol in ethanol 30ml , water 15ml and formic acid 30ml was cooled to ca. SOC and treated portionwise with zinc dust 2.85g, 44mmol . The mixture was then stirred at room temperature for lh, filtered and evaporated. The residue was dissolved in water, washed wih ether 2 x 30ml , adjusted to pH7 and extracted with ethyl acetate 3 x 40ml . The combined extracts were washed with brine, dried and evaporated to give the title compound as an orange oil 0.545g, 52 OH 60MHz, CDCl3 1.22 3H, t, J 7Hz , 1.80 3H, s , 2.80 2H, s , 3.9 4.5 3H, m q, J 7Hz , and 5.0 5.5 and 6.0 7.0 4H, 2m .c. Ethyl 3 methyl 2 2,2,2 trichlorethoxycarbonyl amino hex 3 E , 5 dienoate 2,2,2 Trichlorethyl chloroformate 0.54ml, 3.9mmol was added slowly to a stirred solution of ethyl 2 amino 3methyl hex 3 E ,5 dienoate 0.545g, 3.22mmol in THF 25ml and water 25ml , maintained at pH 7.5. The mixture was stirred for 1.5h, then extracted with ethyl acetate 3 x 25ml . The combined extracts were washed with brine, dried and evaporated to give the crude product as a red oil.Flash chromatography on silica gel, using 0 10 ethyl acetate in hexane as eluant, gave the title compound as a yellow oil 0.745g, 67 SH 250MHz, CDCl3 1.29 3H, t, J 7.1Hz , 1.80 3H, s , 4.24 2H, m , 4.73 2H, s , 4.78 111, d, J 7.4Hz , 5.20 1H, d, J 10.2Hz , 5.29 1H, d, J 16.8Hz , 5.91 1H, br d , 6.18 1H, d, J 10.8Hz , and 6.54 1H, ddd,J 16.8, 10.8, 10.2Hz .d. 3 Methyl 2 2,2,2 trichlorethoxycarbonylamino hex 3 E ,5 dienoic acidEthyl 3 methyl 2 2,2,2 trichlorethoxycarbonylamino hex 3 E ,5 dienoate 0.73g, 2.12mmol in ethanol lOml was stirred with aqueous sodium hydroxide 1M, 2.3ml, 2.3mmol for 1h. The solution was diluted with water, washed with ether 2 x 20ml , acidified and extracted with ethyl acetate 3 x 30ml . The combined extracts were washed with brine, dried and evaporated to yield the title compound as a pale yellow oil 0.530g, 79 bH 60MHz, CD3 2CO 1.9 3H, s , 4.8 2H, s , 4.85 1H, d , 5.1 5.5 2H, m , 6.1 7.2 3H, m , and 9.25 1H, s .e. 6ss D,L 3 Methyl 2 2,2,2 trichlorethoxycarbonylamino hex 3 E ,5 dienamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 71 .f. 6ss 2 Amino 3 methylhex 3 E ,5 dienamido penicillanic acidsDeprotection of GP CD,L 3 methyl 2 2,2,2 trichloro ethoxyearbonylamino hex 3 E ,5 dienamidozpenicillanic acid 0.585g, 1.14mmol was performed as desribed inExample 2c.Chromatography of the crude product onHP20SS, eluting with 0.5 2.5 THF in water, provided 613 L 2 amino 3 methylhex 3 E ,5 dienamido penicillanic acid 70mg, 18 vmax KBr 2970, 1771, 1688, 1598, 1515, 1393 and 1314cm l dH 250MHz, D20 1.48 3H, s , 1.52 3H, s , 1.78 3H, s , 4.24 1H, s , 4.68 1H, s , 5.37 1H, d, J 10.3Hz , 5.44 1H, d, J 4Hz , 5.45 1H, d, J 16.8Hz , 5.59 1H, d, J 4Hz , 6.40 1H, d, J 10.8Hz , and 6.64 1H, ddd, J 16.8, 10.8, 10.3Hz . EMass spectrum ve ion thioglycerol MH 340 followed by a mixture of D and L stereoisomers 100mg, 26 then 6ss D 2 amino 3 methylhex 3 E , 5 dienamido penicillanic acid 58mg, 15 max KBr 3401, 2972, 1766, 1683, 1595, 1395 and 1318cm 1 H 250MHz, D20 1.46 3H, s , 1.55 3H, s , 1.81 3H, d, J 0.6Hz , 4.21 1H, s , 4.63 1H, s , 5.36 111, d, J 10.2Hz , 5.40 5.48 2H, m , 5.54 1H, d, J 3.8Hz , 6.36 1H, d, J 10.9Hz , and 6.65 1H, ddd, J 16.8, 10.9, 10.2Hz . EMass spectrum ve ion thioglycerol MH 340 Example 13 a. Ethyl 3 bromo 2 methoxyiminopropanoateEthyl bromopyruvate 12.6m1, O.lmol and methoxyamine hydrochloride 8.352g, O.lmol were dissolved in ethanol 120m1 and stirred for 2h at room temperature. After evaporation, the residue was taken up in ethyl acetate, washed with water and brine, dried and evaporated. Flash chromatography on silica gel, using 0 12 ethyl acetate in hexane as eluant, gave the title compound as a pale yellow oil 21.4g, 96 Found M , 222.9843. C6H10BrN03 requires M,222.9845 max film 1720, 1370, 1330, 1200, 1180, 1050 and 1020cm 1 250MHz, CDCl3 1.38 3H, t, J 7.1Hz , 4.18 and 4.21 together 3H, 2s, E and Z isomers , 4.17 and 4.36 together 2H, 2s, E and Z isomers , and 4.38 2H, q, J 7.1Hz . b. 2 Ethoxycarbonyl 2 methoxyiminoethyltriphenylphosphonium bromideTriphenylphosphine 34.10g, 0.13mo1 and ethyl 3 bromo 2 methoxyimidopropanate 30.0g, 0.13mol were dissolved in THF 220m1 and refluxed for 5h. After cooling, the product was filtered off, washed with ether and dried to give a white solid 46.51g, 74 , m.p. 137 1390C 9max KBr 1715, 1434, 1108, 1040, 742, 691 and 510cm 1 SH 250MHz, CDCl3 1.15 3H, t, J 7.1Hz , 3.80 3H, s , 4.12 2H, q, J 7.1Hz , 5.25 2H, d, J 16.3Hz , and 7.66 7.90 158, m . A second crop of the title compound was obtained, after a further 30h of refluxing, as a buff powder 9.77g, 15 , m.p.123 1300C.c. Ethyl 2 methoxyiminohex 3 E enoate 2 Ethoxycarbonyl 2 methoxyiminoethyltriphenylphosphonium bromide lOg, 20mmol was dissolved inN,N dimethylpropylene urea DMPU 4ml and THF 20m1 , cooled to ca. 5 C and treated dropwise with n butyllithium 1.6M, 12.8ml, 20mmol . The mixture was then stirred for 1.5h, cooled, and propanal 2m1, 28nmol in THF lOml added slowly. Stirring was continued overnight, the mixture evaporated, the residue suspended in water and extracted with ether 2 x 60ml . The combined extracts were washed with brine, dried and evaporated.Flash chromatography, using 0 5 ethyl acetate in hexane as eluant, gave the title compound as a yellow oil, 1.85g, 50 Found M , 185.1052. CgH1sNO3 requires M , 185.1052 9max film 2970, 2930, 1730, 1260, 1160, 1120 and 1050cm 1 dH 250MHz, CDCl3 1.07 3H, t, J 7.4Hz , 1.37 3H, t,J 7.1Hz , 2.24 2H, m , 4.05 3H, s , 4.34 2H, q, J 7.1Hz , 6.50 1H, dt, J 16.3, 1.5Hz , and 6.77 1H, dt, J 16.3, 6.4Hz other signals corresponding to the Z olefin were present in the spectrum, and integration showed the product to be a 9 1 E Z mixture.d. Ethyl 2 aminohex 3 E enoatePrepared as described in Example 12b 84 max film 2960, 2930, 1730, 1180, 1020, and 970cm 1 H 60MHz, CDCl2 1.0 3H, t, J 7.8Hz , 1.25 3H, t, J 7.2Hz , 2.05 2H, m , 2.55 2H, s , 4.0 4.5 3H, m q, J 7.2Hz , and 5.35 6.2 2H, m .e. Ethyl 2 2,2,2 trichlorethoxycarbonylamino hex 3 E enoatePrepared as described in Example 12c 77 H 60MHz, CDCl3 1.0 3H, t, J 7.5Hz , 1.3 3H, t, J 7.2Hz , 2.1 2H, m , 4.25 2H, q, J 7.2Hz , 4.75 2H, s , 4.95 111, m , and 5.3 6.25 3H, m .f. 2 2,2,2 trichlorethoxycarbonylamino hex 3 E enoic acidPrepared as described in example 12d, using only one equivalent of base 68 , m.p. 120 1210C ethyl acetate cyclohexane Found M H20, 284.9733.C9H10NO3Cl3 requires M, 284.9726 found M C02H, 257.9863. CgHllNO2C13 requires M , 257.9855 9max KBr 3307, 1736, 1710, 1696, 1534, 1249 and 721cm 1 H 250MHz, CD3 2CO 0.99 3H, t, J 7.5Hz , 2.1 2H, m , 4.75 4.87 3H, m , 5.64 1H, ddt, J 15.4, 6.6, 1.5Hz , 5.95 1H, dtd, J 15.4, 6.3, 1.2Hz , and 7.21 1H, br d , also contained a trace of the Z olefin .g. 6ss D,L 2 2,2,2 trichlorethoxycarbonylamino hex 3 E enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 91 . h. 6ss 2 Aminohex 3 E enamido penicillanic acidsDeprotection of 6ss D,L 2 2,2,2 trichlorethoxycarbonylamino hex 3 E enamido penicillanic acid 0.89g, 1.8mmol was performed as described in Example 2c. Chromatography of the crude product on HP20SS, eluting with 1 28 THF in water, provided 6ss L 2 amino hex 3 E enamido penicillanic acid 125mg, 21 vmaX KBr 2967, 1771, 1686, 1602, 1515, 1393 and 1317cm 1 dH 250MHz, D20 0.98 3H, t, J 7.5Hz , 1.50 3H, s , 1.59 3H, s , 2.13 2H, m , 4.25 1H, s , 4.61 1H, d,J 8.4Hz , 5.48 1H, d, J 4.1Hz , 5.59 1H, d, J 4.1Hz , 5.50 5.61 1H, m , and 6.21 1H, dt, J 15.4, 6.3Hz followed by a mixture of D and L stereoisomers 63mg, 11 then 6ss D 2 aminohex 3 E enamido penicillanic acid 80mg, 13 max KBr 2967, 1771, 1687, 1603, 1520, 1393 and 1318cm 1 H 250MHz, D20 1.00 3H, t,J 7.5Hz , 1.49 3H, s , 1.59 3H, s , 2.13 2H, m , 4.23 1H, s , 4.60 1H, d, J 8.6Hz , 5.49 1H, d, J 3.9Hz , 5.55 1H, d, J 3.9Hz , 5.52 5.60 1H, m , and 6.20 1H, dtd, J 15.2, 6.3, 0.5Hz . EMass spectrum ve ion thioglycerol MH 328 ve ion M H 326 .Example 14 a. Ethyl 4 cyclohex 2 methoxyiminobut 3 E enoatePrepared as described in Example 13c, using one equivalent 2Ommol of cyclohexane carboxaldehyde, to give, after chromatography, the title compound 2.60g, 54 Found M , 239.1523. C13H2lNO3 requires M, 239.1521 H 250MHz, CDCl3 1.07 1.3 and 1.6 1.85 10H, 2m , 1.36 3H, t, J 7.1Hz , 2.10 lH, m , 4.04 3H, s , 4.34 2H, q, J 7.1Hz , 6.47 1H, dd, J 16.4, 1.0Hz , and 6.65 1H, dd, J 16.4, 6.8Hz , less than 5 of another isomer was present . b. Ethyl 2 amino 4 cyclohexylbut 3 E enoatePrepared as described in Example 12b 44 H 60MHz, CDCl3 1.0 2.2 14H, m t, J 7Hz , 2.6 2H, s , 4.05 4.5 3H, m d, J 7Hz , and 5.35 6.1 2H, m .c. Ethyl 4 cyclohexyl 2 2,2,2 trichloroethoxy carbonylamino but 3 E enoate Prepared as described in example 12c 42 H 60MHz, CDCl3 1.0 2.3 14H, m t, J 7Hz , 4.25 2H, q, J 7Hz , 4.75 5.05 3H, m s and 5.25 6.15 3H, m .d. 4 Cyclohexyl 2 2,2, 2 trichloroethoxycarbonyl amini but 3 E enoic acidPrepared as described in Example 12d, using one equivalent of base 70 , m.p. 168 1700C ethyl acetate cyclohexane dH 250MHz, CD3 2CO 1.0 1.4 and 1.6 1.8 10H, 2m , 2.01 m under D5 acetone , 4.74 4.86 3H, m , 5.61 1H, ddd, J 15.6, 6.6, 1.1Hz , 5.87 1H, ddd, J 15.6, 6.6, 1.1Hz , and 7.21 1H, br d,J 7.9Hz . EMass spectrum ve ion 3 nitrobenzylalcohol 3 NOBA Na , sodium salt MNa 402 . e. 6ss D,L 4 Cyclohexyl 2 2,2,2 trichloroethoxycarbonylamino but 3 E enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 88 .f. 6ss 2 Amino 4 cyclohexylbut 3 E enamido penicillanic acidsDeprotection of 6ss D,L 4 cyclohexyl 2 2,2,2 trichloro ethoxycarbonylamino but 3 E enamido penicillanic acid 0.628g, l.lmmol was performed as described in Example 2c. Chromatography of the crude product on HP20SS, eluting with 7 25 THF in water, provided 6p L 2 amino 4 cyclohexylbut 3 E enamido penicillanic acid SOmg, 12 9max KBr 2923, 2851, 1759, 1688, 1609, 1511, 1389 and 1319cm 1 dH 250MHz, D20 1.0 1.8 16H, 2m 2s , 2.06 1H, m , 4.25 1H, s , 4.28 111, d,J 7.5Hz , 5.43 5.60 3H, m 2d, J 4.0Hz , and 5.96 1H, dd, J 16.0, 6.6Hz followed by a mixture of D andL stereoisomers 23mg, 5 then 6ss D 2 amino 4 cyclohexylbut 3 E enamido penicillanic acid 80mg, 19 smax KBr 2924, 2850, 1771, 1683, 1599, 1515, 1393 and 1315cm 1 sH 250MHz, D20 1.0 1.8 16H, 2m 2s , 2.05 1H, m , 4.22 1H, s , 4.46 1H, d, J 8.2Hz , 5.43 5.61 3H, m 2d, J 3.9Hz , and 6.05 1H, dd, J 15.6, 6.5Hz . EMass spectrum ve ion thioglycerol MH 382 .Example 15 a. Ethyl 2 methoxyimino 4 phenylbut 3 E enoatePrepared as described in Example 13c, using one equivalent of benzaldehyde, to give, after chromatography, the title compound 77 Found M , 233.1044. C13H15NO3 requires M, 233.1052 H 400MHz, CDCl3 1.40 3H, t, J 7.1Hz , 4.13 3H, s , 4.40 2H, d, J 7.1Hz , 7.22 1H, d, J 16.7Hz , 7.30 7.39 3H, m , 7.51 7.53 2H, m and 7.59 111, d,J 16.7Hz single isomer .b. 2 Methoxyimino 4 phenylbut 3 E enoic acidEthyl 2 methoxyimino 4 phenylbut 3 E enoate 2.91g, 12.5mmol in ethanol 60ml was treated with aqueous sodium hydroxide 1M, 37m1, 37mmol , at room temperature, for 1h. The solution was reduced in volume, diluted with water and washed with ether 2 x 50m1 . The aqueous phase was then acidified to pH2 and extracted with ethyl acetate 3 x 60ml . The combined extracts were washed with brine, dried and evaporated to give a white solid 2.42g , which was recrystallised from ethyl acetate cyclohexane to give colourless needles 2.115g, 82 , m.p. 110 1110C Found C,64.67 H,5.36 N.6.68 .C11H11NO3 requires C,64.38 H,5.40 N, 6.83 H 60MHz, CD3 2CO 4.1 3H, s , 7.25 1H, d, J 17Hz , 7.35 7.70 5H, m , 7.85 1H, d, J 17Hz , and 10.3 1H, br s .c. 2 Amino 4 phenylbut 3 E enoic acid 2 Methoxyimino 4 phenylbut 3 E enoic acid 0.595g, 2.9mmol was dissolved in ethanol 15ml , water 7.5ml and formic acid 15ml , cooled to ca. 50C, and zinc powder 1.0g, 15mmol added portionwise. After five minutes the mixture was filtered and reduced in volume.The solid precipitate was filtered off, washed with acetone then ether, and dried in vacuo to give the title compound as a white crystalline solid 0.450g, 88 , m.p. 197 1990C 9max KBr 2946, 1646, 1585, 1396, 1354, 1331, 962 and 734 cm l H 250MHz, D20 DC1 4.53 1H, dd, J 8.5, 0.4Hz , 6.00 1H, dd,J 15.9, 8.4Hz , 6.65 1H, dd, J 15.9, 0.4Hz , and 7.05 7.23 5H, m . Mass spectrum ve ion ammmonia MH 178 . The aqueous filtrate afforded a second crop of the title compound, after HP20SS chromatography, 37mg, 7 .d. 4 Phenyl 2 2,2,2 trichlorethoxycarbonylamino but 3 E enoic acid 2 Amino 4 phenylbut 3 E enoic acid 0.46g, 2.5mmol was suspended in water 15ml and THF 15ml and treated dropwise with 2,2,2 trichloroethyl chloroformate 0.5ml, 3.6mmol in THF 5ml , while maintaining the pH at 7.7 0.2. The mixture was stirred for one hour, reduced in volume, washed with ether 2 x 30m1 , acidified and extracted with ethyl acetate 3 x 30ml . The combined extracts were washed with brine, dried and evaporated.Recrystallisation, from ethyl acetate cyclohexane, gave the title compound as a buff powder 295mg, 40 , m.p. 205 2070C OH 250MHz, CD3 2CO 4.85 and 4.88 2H, ABq, J 12.2Hz , 5.03 1H, m , 6.46 1H, dd, J 16.0, 6.7Hz , 6.84 1H, d, J 16.0Hz , and 7.25 7.50 6H, m . tMass spectrum M 351 , M C02 306 .e. 6ss D,L 4 Phenyl 2 2,2,2 trichlorethoxycarbonyl amino but 3 E enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 82 .f. 6ss 2 Amino 4 phenylbut 3 E enamido penicillanic acidsDeprotection of 6p D,L 4 phenyl 2 2,2,2 tri chlorethoxycarbonylamino but 3 E enamido penicillanic acid 1.4g, 2.5mmol was performed as described inExample 2c. Chromatography of the crude product onHP20SS, eluting with 5 25 THF in water, provided 6ss L 2 amino 4 phenylbut 3 E enamido penicillanic acid 46mg, 5 max KBr 2970, 1773, 1690, 1602, 1517, 1395 and 1315cm 1, H 250MHz, D2O 1.45 6H, 8 , 4.22 1H, s , 4.8 1H obscured by HOD , 5.49 1H, d, J 4.0Hz , 5.60 1H, d, J 4.0Hz , 6.31 111, dd, J 15.9, 8.5Hz , 7.01 1H, d, J 15.9Hz ,.and 7.36 7.58 5H, m followed by a mixture of D and Lstereoisomers 106mg, 11 then 6ss D 2 amini 4 phenylbut 3 E enamido penicillanic acid 80mg, 9 smax KBr 2971, 1772, 1689, 1599, 1517, 1395 and 1317cm 1 H 250MHz, D2O 1.40 6H, s , 4.19 1H, s , 4.8 1H obscured by HOD , 5.45 1H, d, J 3.7Hz .5.55 1H, d, J 3.7Hz , 6.29 1H, dd, J 15.9, 8.6Hz , 7.0 1H, d, J 15.9Hz , and 7.40 7.57 5H, m . Mass spectrum ve ion thioglycerol MH 376 .Example 16 a. Ethyl 4 4 chlorphenyl 2 methoxyiminobut 3 E enoatePrepared as described in Example 13c, using 0.97 equivalents 29mmol of 4 chlorobenzaldehyde, to give, after chromatography, the title compound 3.31g, 43 H 60MHz, CDCl3 1.4 3H, t, J 7Hz , 4.1 3H, s , 4.4 2H, q, J 7Hz , 7.1 111, d, J 17Hz , 7.1 7.4 4H, m , and 7.6 1H, d, J 17Hz . Mass spectrum M 269 .b. 4 4 Chlorophenyl 2 methoxyiminobut 3 E enoic acidPrepared as described in Example 15b 1.735g, 78 , m.p. 73 80 C cyclohexane H 60MHz, CDCl3 2CO 4.1 3H, s , 7.1 1H, d, J 17Hz , 7.5 4H, m , 7.8 1H, d,J 17Hz , and 10.7 1H, br s . c. 2 Amino 4 4 chlorophenyl but 3 E enoic acidPrepared as described in Example 15c 1.213g, 80 max KBr 2950, 1643, 1586, 1490, 1392, 964 and 817cm 1 H 250MHz, D2O DCl 4.38 1H, dd, J 8.4, 0.6Hz , 5.82 1H, dd, J 15.8, 8.4Hz , 6.45 1H, d, J 15.8Hz , and 6.87 7.00 4H, m .d. 4 4 Chlorophenyl 2 2,2,2 trichlorethoxy carbonylamino but 3 E enoic acidPrepared as described in Example 15d 0.784g, 368 , m.p. 188 1930C ethyl acetate cyclohexane Vmax KBr 1728, 1510, 1491, 1406, 1246, 1093 and 809cm 1 H 250MHz, CD3 2CO 4.83 and 4.86 2H, ABq,J 12.2Hz , 5.03 1H, m , 6.49 1H, dd, J 16.0, 6.6Hz , 6.84 1H, dd, J 16.0, 0.9Hz and 7.36 7.54 58, m . Mass spectrum M 385 , M CO2H 340 .e. 6ss D,L 4 4 chlorophenyl 2 2,2,2 trichloro ethoxycarbonylamino but 3 E enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 79 .f. 6ss D,L 2 Amino 4 4 chlorophenyl but 3 E enamido penicillanic acidDeprotection of 6P CD,E 4 4 chlorophenyl 2 2,2,2 trichloroethoxyearbonylamino but 3 E enamido penicill anic acid 0.89g, 1.5mmol was performed as described in Example 2c.Chromatography of the crude product onHP20SS, eluting with 10 35 THF in water, provided the title compound 158mg, 27 human KBr 1773, 1688, 1594, 1513, 1491, 1392 and 1317cm 1 dH 250MHz, D20 1.37 3H, s , 1.43 3H, s , 4.17 and 4.20 together 1H, 2s , 4.8 1H obscured by HOD , 5.42 and 5.47 together 1H, 2d, J 3.7, 4.1Hz ,5.53 and 5.58 together 111, 2d,J 3.7, 4.1Hz , 6.2 6.35 together 1H, 2dd, J 15.9, 8.6Hz , 6.94 and 6.96 together 1H, 2d, J 15.9Hz , and 7.36 7.50 4H, m . Mass spectrum ve ion thioglycerol MH 410 .Example 17 a. Ethyl 2 methoxyimino 4 trifluoromethyl 3enoateMethyltriphenylphosphonium bromide 7.145g, 20mmol was suspended in THF 100ml , cooled to ca. 250C, and n butyllithium 1.5M, 13.3ml, 20mmol added slowly. The mixture was stirred at 200C for 1.5h, cooled to ca. 700C and ethyl 2 methoxyimino 3 oxo 4,4,4 trifluorobutanoate 4.543g, 20mmol for preparation seeC. Scolastico et.al., Synthesis, 1985, 850 in THF 20ml added slowly. The mixture was then stirred while warming slowly to room temperature and overnight at room temperature. The mixture was then evaporated, the residue dissolved in ethyl acetate, washed with water and brine, dried and evaporated. The crude product was purified by flash chromatography on silica gel, using 0 5 ethyl acetate in hexane as eluant, to give the title compound as a volatile, colourless oil 1.13g, 25 H 60MHz, CDC13 1.35 3H, t, J 7Hz , 4.05 3H, s , 4.4 2H, q, J 7Hz , and 5.85 and 6.25 2H, 2m .b. Ethyl 2 amino 3 trifluoromethylbut 3 enoatePrepared as described in Example 12b 0.70g, 71 SH 60MHz, CDC13 1.25 3H, t, J 7Hz , 2.0 2H, br s , 4.25 3H, m q, J J 7Hz , and 5.85 and 6.0 2H, 2m .c. Ethyl 2 2,2,2 trichloroethoxycarbonylamino 3trifluoromethylbut 3 enoatePrepared as described in Example 12c 1.3g, quantitative H 60MHz, CDC13 1.3 3H, t, J 7Hz , 4.35 2H, q, J 7Hz , 4.8 2H, s , 5.25 1H, d, J 8Hz 5.95 and 6.15 2H, 2m , and 6.35 1H, br d, J 8Hz . Mass spectrum M 371 .d. 2 2,2,2 trichloroethoxycarbonylamino 3 trifluoromethylbut 3 enoic acidPrepared as described in Example 12d 0.965g, 808 sH 60MHz, CD3 2CO 4.85 2H, s , 5.15 1H, d, J 8Hz , 6 6.3 2H, m and 7.4 1H, br d, J 8Hz . e. 6,ss D,L 2 2,2,2 trichloroethoxycarbonylamino 3 trifluoromethylbut 3 enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 1.32g, 87 .f. 6,ss 2 Amino 3 trifluoromethylbut 3 enamido penicillanic acidsDeprotection of 6ss D,L 2 2,2,2 trichloroethoxycarbonylamino 3 trifluoromethylbut 3 enamido penicillanic acid 1.32g, 2.4mmol was performed as described in Example 2c. Chromatography of the crude product on HP20SS, eluting with 0.5 3 THF in water, provided 6ss L 2 amini 3 trifluoromethylbut 3 enamido penicillanic acid 80mg, 9 9max KBr 1774, 1694, 1607, 1516, 1314, 1174 and 1130cm 1 H 250MHz, D20 1.50 3H, s , 1.59 3H, s , 4.25 1H, s , 4.99 1H, s , 5.50 1H, d, J 4.0Hz , 5.59 1H, d, J 4.0Hz , and 6.19 and 6.41 2H, 2 br s followed by a mixture of D andL stereoisomers 72mg, 8 then 6, D 2 amino 3 trifluoromethylbut 3 enamido penicillanic acid 60mg, 7 max KBr 1772, 1694, 1520, 1318, 1246, 1176 and 1129cm 1 H 250MHz, D20 1.49 3H, s , 1.60 3H, s , 4.22 1H, s , 4.96 1H, s , 5.55 1H, d, J 3.9Hz , 5.58 1H, d, J 3.9Hz , and 6.21 and 6.42 2H, 2 br s . Mass spectrum ve ion thioglycerol MH 368 . Example 18 a. Methyl 5 chloromethyl 5 thien 2 yl 2 oxazolin 4ylcarboxylateCuprous oxide 0.05g was added to 2 chloroacetylthiophene 1.61g, lOmmol and methyl isocyanoacetate 0.91ml, lOmmol in toluene 25ml then the mixture was stirred and heated at 700C for 5h. The reaction mixture was concentrated in vacuo and the residue flash chromatographed on silica gel to give the title compound 1.49g, 57 Found M , 259.0067.C10H10ClNO3S requires M, 259.0069 H 60MHz, CDCl3 3.33 3H, s , 4.00 2H, s , 5.02 1H, d, J 2Hz , and 6.8 7.4 4H, m .b. Methyl 2 formamido 3 thien 2 ylbut 3 enoateActivated zinc dust 2.3g was added to methyl 5 chloromethyl 5 thien 2 yl 2 oxazolin 4 ylcarboxylate 4.59g in THF 25ml under argon and heated under reflux for 2h. Ethyl acetate 50ml and 0.5N hydrochloric acid 50ml were added, the mixture filtered and the filtrate extracted twice more with ethyl acetate. The extracts were washed with brine 3 x 50ml , dried, the solvent evaporated and the residue flash chromatographed on silica gel to give the title compound 3.01g, 61 Found M , 225.0460. C10H11NO3S requires M, 225.0460 OH 60MHz, CDCl3 3.78 3H, s , 5.28 1H, s , 5.62 1H, s , 5.65 1H, d, J 8Hz , 6.74 1H, br d, J 8Hz, exch D20 , 6.9 7.3 3H, m , and 8.25 1H, s . c. Methyl 2 amino 3 thien 2 ylbut 3 enoate hydrochlorideMethanol was added to methyl 2 formamido 3 thien 3ylbut 3 enoate 1.04g in 5N hydrochloric acid lOml to give a homogeneous solution which was stirred overnight then evaporated in vacuo to give the title compound as a crude foam 0.99g, 92 611 60MHz, CD3OD 3.83 3H, s , 5.23 1H, s , 5.55 1H, s , 5.83 1H, s , and 6.9 7.5 3H, m .d. Methyl 3 thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 enoateMethyl 2 amino 3 thien 2 ylbut 3 enoate hydrochloride 0.99g, 4.2mmole in 50 aqueous THF 40ml was maintained at pH71 0.5 with 2.5N sodium hydroxide solution while 2,2,2 trichloroethyl chloroformate 0.725ml, 5.25mmol was added dropwise. The solution was stirred for a further 0.5h at pH 7 0.5 then extracted with chloroform 3 x 25ml . The extracts were washed with water 2 x 50m1 , dried, the solvent evaporated in vacuo and the residue flash chromatographed on silica gel to provide the title compound 0.95g, 61 Found M , 370.9557.C12H12Cl3NO4S requires M, 370.9553 8H 60MHz,CDCl3 3.77 3rr s , 4.73 2H, s , 5.28 111, 5 , 5.33 1H, d, J 8Hz 5.63 111, s , 6.18 111, br d, J 8Hz, exch D20 , and 6.85 7.3 3H, m .e. 3 Thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 enoic acidMethyl 3 thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 enoate 1.54g 4.lmmol in N sodium hydroxide 5ml and methanol 5ml was stirred for 2h.The solution was washed with chloroform 2 x lOml , acidified to pH2.5 and extracted with chloroform 3 x 15ml . The extracts were washed with water 25ml , dried, the solvent evaporated in vacuo and the residue flash chromatographed on silica gel to give the title compound 1.04g, 70 H 60MHz, CD3 2CO 4.83 2H, s , 5.37 111, d, J 8Hz , 5.38 1H, s , 5.65 111, 8 , 6.9 7.5 411, m , and 8.47 111, br s, exch D2O .f. 6ss D,L 3 Thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 enamido penicillanic acidPrepared as described in Example 2b but the title compound isolated as the crude free acid 82 .g. 6ss 2 Amini 3 thien 2 ylbut 3 enamido penicillanic acids 6p ED,L 3 Thien 2 yl 2 2,2,2 trichloroethoxyearbonyl amino but 3 enamido penicillanic acid 1.14g was deprotected as described in Example 2c. The crude product was chromatographed on HP20SS in 3 THF water to give 6ss L 2 amino 3 thien 2 ylbut 3 enamido penicillanic acid 15mg , max KBr 3349, 1766, 1669, 1601 and 1515cm 1 H 250MHz, D20 1.42 3H, s , 1.46 3H, s , 4.19 1H, s , 5.09 1H, s , 5.46 1H, d, J 4.1Hz , 5.52 1H, s , 5.58 111, d, J 4.1Hz , 5.87 1H, s , and 7.0 7.5 3H, m followed by a mixture of D andL stereoisomers 15mg then 6ss D 2 amin 3 thien 2 yl but 3 enamido penicillanic acid 16mg 9max KBr 3373, 1766, 1675, 1599 and 1516cm 1 H 250MHz, D20 1.44 3H, s , 1.52 3H, s , 4.17 1H, s , 4.97 1H, s , 5.47 1H, d, J 3.9Hz , 5.48 111, s , 5.53 1H, d, J 3.9Hz , 5.82 1H, s , and 7.05 7.45 3H, m . Mass spectrum ve ion thioglycerol MH 382 , MNa 404 . Example 19 a. 2 Dichloroacetyl thiopheneSulphuryl chloride 21ml was added dropwise to 2 acetylthiophene 16.2ml in carbon tetrachloride 50m1 cooled in a water bath. The mixture was stirred for 1.5h then distilled to provide the title compound 19.19g , b.p. 144 148 C 12mm H 60MHz, CDCl3 6.50 1H, s , and 7.1 8.1 3H, m containing ca. 30 2 chloroacetyl thiophene, 5H inter alia 4.60 2H, s .b. Methyl 5 dichloromethyl 5 thien 2 yl 2 oxazolin4 ylcarboxylate 2 Dichloroacetyl thiophene 6.77g, 34.5mmol, mixed with 2 chloroacetyl thiophene 2.37g was added dropwise to methyl isocyanoacetate 2.3ml, 30mmol and triethylamine 4.3ml, 30mmol in toluene 30ml cooled in an ice bath. The reaction was stirred for 24h at room temperature e then acetic acid 1.8m1 added followed by ethyl acetate 100ml . The mixture was washed with water 2 x 50ml and brine 50ml , dried, concentrated and flash chromatographed on silica gel to give the title compound 7.30g, 83 Found M , 292.9668. C10H9Cl2NO3S requires M, 292.9680 H 250MHz, CDCl3 3.43 3H, s , 5.13 and 5.26 together 1H, 2d, J 2Hz, isomer ratio 1 4 , 6.00 and 6.46 together 1H, 2s, ratio 4 1 , and 7.0 7.4 411, m .c. Methyl 4 chloro 2 formamido 3 thien 2 ylbut 3enoateMethyl 5 dichloromethyl 5 thien 2 yl 2 oxazolin 4 ylcarboxylate was treated with activated zinc dust in THF as described in Example 18b. The crude product was chromatographed on silica gel to give the E isomer of the title compound 9 . A sample was crystallised from ethyl acetate hexane, m.p. 92 930C Found C, 46.29 H, 3.89 N, 5.43 Cl, 13.71, S, 12.18 . C10H10ClNO3S requires C, 46.25 H, 3.88 N, 5.39 C1, 13.65 S, 12.35 H 60MHz, CDC13 , 3.80 38, s , 6.11 1H, d, J 8Hz , 6.62 1H, s , 6.87 111, br d, J 8Hz, exch D20 , 6.9 7.4 3H, m , and 8.23 1H, s .Further elution of the column and crystallisation from ethyl acetate hexane gave the Z isomer of the title compound 42 , m.p. 117 90C Found C, 46.35 H, 3.87 N, 5.36 C1, 13.47 S, 12.41 . C10H10ClNO3S requires C, 46.25 H, 3.88 N, 5.39 C1, 13.65 S, 12.35 H 250MHz, CDCl3 3.79 3H, s , 5.59 1H, d, J 7.7Hz , 6.56 1H, br d, J 7.7Hz , 6.61 1H, s , 7.05 7.45 3H, m , and 8.23 1H, s . Confirmed asZ isomer by N.O.E. d. Methyl 2 amino 4 chloro 3 thien 2 ylbut 3 Z enoate hydrochlorideMethyl 4 chloro 2 formamido 3 thien 2 ylbut 3 Z enoate 0.97g was hydrolysed as described in Example 18c.The title compound was obtained as a crystalline solid by trituration of the crude product with ether 0.80g , m.p. 190 10C Found C, 40.03 H, 4.14 N, 5.25 S, 12.21 . C9H11Cl2NO2S requires C, 40.31 H, 4.13 N, 5.22 S, 11.96 H 60Mhz, CD30D 3.90 3H, s , 5.33 1H, s , 7.07 1H, s , and 7.1 7.8 3H, m .e. Methyl 4 chloro 3 thien 2 yl 2 2 trichloroethoxycarbonylamino but 3 Z enoateMethyl 2 amino 4 chloro 3 thien 2 ylbut 3 Z enoate hydrochloride 1.22g was acylated with 2,2,2trichloroethyl chloroformate 0.665m1 as described inExample 18d. The title compound was crystallised from hexane 1.42g, 77 , m.p. 66 70C Found C, 35.55 H, 2.66 N, 3.39 C1, 34.79 S, 7.82 . C12H11Cl4N04S requires C, 35.40 H, 2.72 N, 3.44 C1, 34.83 S, 7.88 dH 60MHz, CDC13 3.77 3H, s , 4.73 2H, s , 5.25 1H, d, J 8Hz , 6.07 1H, br d, J 8Hz, exch D20 , 6.58 1H, s , and 6.95 7.5 3H, m . f. 4 Chloro 3 thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 Z enoic acidMethyl 4 chloro 3 thien 2 yl 2 2, 2,2 trichloroethoxy carbonylamino but 3 Z enoate 1.42g was bydrolysed as described in Example 18e. The title compound was crystallised from ethyl acetate hexane 0.151g, 37 , m.p. 112 30C Found M , 390.9009. CllHgCl4NO4S requires M, 390.9007 oH 60MHz, CD3 2CO 4.77 3H, s , 5.38 1H, d, J 8Hz , 6.70 1H, s , 6.9 7.5 4H, m , and 9.80 1H, br s, exch D20 . g. 6R D,L 4 Chloro 3 thien 2 yl 2 2,2,2 trichloro ethoxycarbonylamino but 3 Z enamido penicillanic acidPrepared as described in Example 2b but the title compound was isolated as the crude free acid 77 .h. 6ss D,L 2 Amino 4 chloro 3 thien 2 ylbut 3 Z enamido penicillanic acid 6n ED,L 4 Chloro 3 thien 2yl 2 2,2,2 trichloroethoxy carbonylamino but 3 Z enamido penicillanic acid was deprotected as described in example 2c. The title compound was isolated as a white freeze dried solid after chromatography on HP20SS 7 smax KBr 3379, 1771, 1688, 1601, 1515 and 708cml SH 250MHz, D20 1.45, 1.47 and 1.56 together 6H, 3s , 4.20 and 4.22 together 1H, 2s , 5.18 and 5.20 together 1H,2s , 5.45 and 5.54 together 1H, 2d, J 4Hz , 5.59 and 5.60 together 1H, 2d, J 4Hz , 7.00 and 7.02 together 1H, 2s , and 7.1 7.2 3H, m . Mass spectrum ve ion glycerol DMSO MH 416 , 2M H 831 .Example 20 a. Methyl 2 amino 4 chloro 3 thien 2 ylbut 3 E enoate hydrochlorideMethyl 4 chloro 2 formamido 3 thein 2 ylbut 3 E enoate 0.50g, from Example 19c was hydrolyed as described inExample 18c. The title compound was obtained as a crude foam 0.50g, 96 H 60MHz, CD30D 3.85 3H, 8 , 5.57 111, s , 6.97 111, 8 , and 7.0 7.6 3H, m .b. Methyl 4 chloro 3 thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 E enoateMethyl 2 amino 4 chloro 3 thien 2 ylbut 3 E enoate hydrochloride 0.50g was acylated as described inExample 18d. The title compound was crystallised from hexane 0.63g, 84 , m.p. 67 90C Found C,35.64 H, 2.62 N, 3.28 C1, 34.86 S, 7.93 . C12H11Cl4NO4S requires C, 35.40 H, 2.72 N, 3.44 C1, 34.83 S, 7.88 H 60MHz, CDCl3 3.78 3H, s , 4.73 2H, s , 5.83 1H, d, J 8Hz , 6.15 1H, d, J 8Hz , 6.60 1H, s , and 6.85 7.3 3H, m .c. 4 Chloro 3 thien 2 yl 2 2,2,2 trichloroethoxy carbonylamino but 3 E enoic acidMethyl 2 amino 3 thien 2 yl 2 2,2,2 trichloroethoxycarbonylamino but 3 E enoate 0. 52g , was hydrolysed as described in Example 18e to give the title compound as a foam 0.45g, 86 H 60MHz, CD3 2CO 4.77 2H, s , 5.88 1H, d, J 7Hz , 6.78 1H, s , 6.9 7.5 4H, m , and 9.20 1H, br s, exch D20 .d. 6 3 ED,L 4 Chloro 3 thien 2 yl 2 2,2,2 trichloro ethoxycarbonylamino but 3 E enamido penicillanic acidPrepared as described in Example 2b to give the title compound as the free acid quantitative .e. 6ss D,L 2 Amino 4 chloro 3 thien 2 ylbut 3 E enamido penicillanic acid 6ss D,L 4 Chloro 3 thien 2 yl 2 2,2,2 trichloroethoxy carbonylamino but 3 E enamido penicillanic acid 0.67g was deprotected as described in Example 2c.Chromatography on HP20SS gave the title compound isolated as a white freeze dried solid 25mg, 5 max KBr 3339, 1774, 1688, 1599, 1511 and 709 cm 1 H 250MHz, D20 1.43, 1.46 and 1.55 together 6H, 3s , 4.18 and 4.21 together 1H, 2s , 5.43 and 5.47 together 1H, 2d, J 4Hz , 5.55 5.7 2H, m , and 7.0 7.5 4H, m . Mass spectrum ve ion 3 NOBA Na MNa 438 , MNa Na salt 460 . Example 21 a. Methyl 5 dichloromethyl 5 methyl 2 oxazolin 4 ylcarboxylate l,l Dichloroacetone 9.6ml and methyl isocyanoacetate 6.9ml were reacted in the presence of triethylamine 12.9ml using the method described in Example 19b to give the title compound as an oil 17.14g, 84 H 60MHz, CDCl3 1.52 3H, s , 3.67 3H, s , 4.72 1H, d, J 2Hz , 5.53 1H, s , and 6.72 1H, d, J 2Hz . Mass spectrum ve ion ammonia MH 226 .b. Methyl 4 chloro 2 formamido 3 methylbut 3 enoateMethyl 5 dichloromethyl 5 methyl 2 oxazolin 4ylcarboxylate was treated with activated zinc dust as described in Example 18b. The crude product was chromatographed on silica to give the Z isomer of the title compound as a colourless oil 3 Found M , 190.0265. C7HgClN03 requires M, 190.0271 dH 60MHz, CDCl3 1.78 3H, br s , 3.82 3H, s , 5.75 111, d,J 7Hz , 6.12 1H, br s , 6.87 1H, br a, exch D20 , and 8.27 1H, s . Further elution of the column provided the E isomer of the title compound, which was crystallised from ethyl acetate hexane 13 , mXp. 103 50C Found C, 44.00 H, 5.30 N,7.25 C1. 18.88 . C7HloClNO3 requires C, 43.88 H, 5.26 N, 7.31 Cl, 18.50 6H 250MHz, CDCl3 1.76 3H, d, J 3Hz , 3.80 3H, s , 5.19 111, d, J 7.4Hz , 6.32 1H, m , 6.61 1H, br S, exchD2O , and 8.23 1H, s . Confirmed as E isomer by N.O.E. c. Methyl 2 amino 4 chloro 3 methylbut 3 E enoate hydrochlorideMethyl 4 chloro 2 formamido 3 methylbut 3 E enoate 1.56g was bydrolyed as described in Example 18c. The crude produce was triturated with ether to give the title compound as a crystalline solid 1.42g, 88 , m.p. 169 71 C dec H 60MHz, CD30D 1.82 3H, s , 3.83 3H, s , 4.92 1H, s , and 6.68 1H, br s .d. Methyl 4 chloro 3 methyl 2 2,2,2 trichloroethoxy carbonylamino but 3 E enoate Methyl 2 amino 4 chloro 3 methylbut 3 E enoate hydrochloride 1.00g was acylated as described inExample 18d. The title compound was crystallised from hexane 1.06g, 63 , m.p. 79 820C Found C, 31.67 H, 3.19 N, 4.18 C1, 41.41 . C9H11Cl4N04 requiresC,31.89 H, 3.27 N, 4.13 C1, 41.83 H 60MHz, CDCl3 1.78 3H, br s ,3.80 3H, s , 4.72 2H, s , 4.87 1H, d, J 8Hz , 6.07 1H, br d, J 8Hz, exch D20 , and 6.32 1H, br s . e. 4 Chloro 3 methyl 2 2,2,2 trichloroethoxy carbonylamino but 3 E enoic acidMethyl 4 chloro 2 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 E enoate 0.51g was hydrolysed as described in Example 18e to give the title compound as a gum 0.41g, 84 Found M C1, 287.9599, C8HgC13N04 requires M, 287.9598 M C02H, 277.9310. C7H8C14N02 requires M, 277.9309 H 60MHz, CDCl3 1.87 3H, br s , 4.80 2H, s , 4.93 1H, d, J 8Hz , 6.48 1H, br s , 7.31 1H, br d, J 8Hz, exch D20 , and 7.82 1H, br s, exch D20 . f. 6ss D,L 4 Chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 E enamido penicillanic acidPrepared as described in example 2b, to give the title compound as the free acid 88 .g. 6ss 2 Amino 4 chloro 3 methylbut 3 E enamido penicillanic acids 6ss D,L 4 Chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 E enamido penicillanic acid 0.58g was deprotected as described in Example 2c.The crude product was chromatographed on HP20SS to give the L stereoisomer of the title compound 52mg, 14 9max 3368, 1766, 1683, 1602 and 1511 cm 1 6H 250MHz, D20 1.50 3H, s , 1.58 3H, s , 1.80 3H, d,J 1.5Hz , 4.25 1H, s , 4.65 1H, s , 5.45 1H, d, J 4Hz , 5.58 1H, d, J 4Hz , and 6.59 1H, br s followed by a mixture of D and L stereoisomers 26mg, 7 then the D stereoisomer of the title compound 59mg, 15 max KBr 3382, 1767, 1685, 1602 and 1521 cm 1 dH 250MHz, D20 1.49 3H, s , 1.59 3H, s , 1.82 3H, d, J 1.3Hz , 4.22 1H, s , 4.70 1H, s , 5.47 1H, d, J 3.8Hz , 5.55 1H, d, J 3.8Hz , and 6.60 1H, br s Mass spectrum ve ion thioglycerol MH 348 .Example 22 a. Methyl 2 amino 4 chloro 3 methylbut 3 Z enoate hydrochlorideMethyl 4 chloro 2 formamido 3 methylbut 3 Z enoate 0.78g, from Example 21b was hydrolyed as described inExample 18c to give the title compound as a foam 0.68g, 84 6H 60MHz, CD30D 1.88 3H, br s , 3.90 3H, s , 5.30 1H, s , and 6.58 1H, br s . b. Methyl 4 chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 Z enoateMethyl 2 amino 4 chloro 3 methylbut 3 Z enoate hydrochloride 0.68g was acylated as described inExample 18d. The title compound was crystallised from hexane 0.66g, 58 , m.p. 1103O dH 60MHz, CDCl3 1.82 3H, br s , 3.86 3H, s , 4.80 2H, s , 5.62 1H, d, J 8Hz , 6.18 1H, br s , and 6.30 1H, br d, J 8Hz, exch D20 . Mass spectrum ,M C1 302 , M C02CH3 278 .c. 4 Chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 Z enoic acidMethyl 4 Chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 Z enoate 0.41g was hydrolysed as described in Example 18e. The title compound was crystallised from ethyl acetate hexane 0.21g, 53 , m.p. 1324O dH 60MHz, CDC13 1.83 3H, d, J 1Hz , 4.75 2H, s , 5.56 1H, d, J 7Hz , 6.23 1H, q, J 1Hz , 6.98 1H, br dr J 7Hz , and 8.07 1H, br s .d. 613 D,L 4 Chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 Z enamido penicillanic acidPrepared as described in Example 2b to give the title compound, isolated as the free acid 52 .e. 6R D,L 2 Amino 4 chloro 3 methylbut 3 Z enamido penicillanic acid 6ss D,L 4 Chloro 3 methyl 2 2,2,2 trichloroethoxycarbonylamino but 3 Z enamido penicillanic acid 0.54g was deprotected as described in Example 2c to give the title compound isolated by chromatography onHP20SS, as a white freeze dried solid 0.10g, 28 max KBr 3344, 1771, 1688, 1602, 1514 and 1313cm 1 6H 250MHz, D20 1.49, 1.50, 1.57 and 1.60 together 6H, 4s , 1.79 and 1.80 together 3H, 2d, J 1.6Hz , 4.24 and 4.25 together 1H, 2s , 5.20 and 5.21 together 1H, 2s , 5.47 and 5.52 together 1H, 2d, J 4Hz , 5.56 and 5.60 together 1H, 2d, J 4Hz , and 6.45 1H, br s . Mass spectrum ve ion thioglycerol MH 348 .Example 23 a. D 2 2,2, 2 Trichloroethoxycarbonylamino pent 4 enoic acidD 2 Aminopent 4 enoic acid hydrochloride 2.33g in aqueous THF at pH 8 1, was acylated with 2,2,2 trichloroethyl chloroformate 2.5m1 using the method described in Example 2a. Flash chromatography gave the title compound as a colourless oil 2.92g, 55 dH 60MHz, CD3 2CO 2.4 2.8 2H, m , 4.2 4.6 1H, m , 4.80 2H, s , 5.0 5.4 2H, m , 5.6 6.3 1H, m , 7.75 1H, d, J 8Hz , and 8.99 1H, s .b. Benzhydryl D 2 2,2,2 trichloroethoxycarbonyl amino pent 4 enoate Diphenyldiazomethane 1.63g in dichloromethane 20ml was added dropwise over 20 minutes to D 2 2,2,2 trichloroethoxycarbonylamino pent 4 enoic acid 2.9g in dichloromethane. At the end of the addition, all the pink colour had disappeared so further diphenyldiazomethane 0.19g in dichloromethane was added and then again to give a permanent pink colour. Glacial acetic acid was added to decolourise the solution after lh.Then the mixture was concentrated in vacuo to an oil which solidified on standing overnight. The title compound was obtained from hexane 3.87g, 91 , m.p.84 87.50C max KBr 3357, 1743, 1725, 1534, 1270, 1238, 1220, 1107 and 702cm lt 6H 60MHz, CD3 2C0 2.4 2.9 2H, m , 4.3 4.8 1H, m 4.82 2H, s , 4.9 5.4 2H, m , 5.6 6.3 1H, m , 6.98 1H, s , and 7.44 10H, s .c. Benzhydryl 3 hydroxy D 2 2,2,2 trichloroethoxycarbonylamino pent 4 enoate t Butyl hydroperoxide, 70 aqueous solution 1.85ml in dichloroethane ca. 40ml was dried over MgS04 and filtered. This solution was added to benzhydryl 2 2,2,2 trichloroethoxyearbonylamino pent 4 enoate 3.30g and selenium dioxide 0.36g . The mixture was stirred at 710C for 3.5h under reflux, and then stirred at room temperature over a weekend. The liquor was decanted off, partially concentrated in vacuo and the title compound 0.94g, 28 obtained after flash chromatography on silica gel.Unreacted starting material 2.10g, 64 , was recovered and treated as above to yield the title compound 0.90g, 42 . The overall yield after two passes was 54 . sH 60MHz, CD3 2CO 4.7 2H, s , 4.4 5.5 4H, m , 5.5 6.3 1H, m , 6.7 1H, d, J 9Hz , 6.87 1H, s , and 7.4 10H, s . d. Benzhydryl 3 acetoxy D 2 2,2,2 trichloroethoxycarbonylamino pent 4 enoateAcetic anhydride 0.06g was added to benzhydryl 3 hydroxy D 2 2, 2, 2 trichloroethoxycarbonylamino pent 4 enoate 0.29g and 4 dimethylaminopyridine lmg in pyridine 5ml . The reaction mixture was stirred under argon at room temperature for 6h. The mixture was diluted with water, acidified and extracted with ethyl acetate 2 x 30ml . The combined organic extracts were washed with water 2 x 30ml and brine, dried and concentrated in vacuo.The title compound was obtained as a mixture of D and L O acetyl isomers after flash chromatography on silica 0.21g, 67 SH 60MHz, CDCl3 1.76 and 1.93 together 3H, 2s , 4.76 2H, s , 4.6 4.9 1H, m , 5.1 6.2 5H, m , 6.95 1H, s , and 7.36 10H, s . Mass spectrum ve ion 3 NOBA, Na MNa 536 e. Benzhydryl 5 acetoxy D 2 2,2,2 trichloroethoxy carbonylamino pent 3 enoate Benzhydryl 3 acetoxy D 2 2,2,2 trichloroethoxycarbonylamino pent 4 enoate 1.35g and bis acetonitrile palladium II chloride 65mg in dryTHF were stirred for 24h at room temperature, open to the atmosphere.The mixture was concentrated in vacuo and the title compound obtained after flash chromatography on silica 0.85g, 63 H 60MHz, CDCl3 1.97 3H1 s , 4.45 4.65 2H, m , 4.i2 2H, s , 5.1 1H, br d , 5.8 6.0 2H, m , 6.1 1H, d, J 8Hz , 6.97 1H, s , and 7.33 10H, s .f. 5 Acetoxy D 2 2,2,2 trichloroethoxycarbonylamino pent 3 enoic acidTrifluoroacetic acid 4.5ml and anisole 0.63m1 were mixed and added to benzhydryl 5 acetoxy D 2 2,2,2trichloroethoxycarbonylamino pent 3 enoate 0. 70g . The mixture was stirred at room temperature for 6 minutes, then diluted with toluene and concentrated in vacuo, this was repeated twice. After flash chromatography, the title compound was, obtained by trituration from hexane 0.33g, 69 , m.p. 94.5 970C Vmax KBr 3413, 3000 br , 2995, 1734, 1694, 1533, 1403, 1328, 1227, 1196, 1101, 823, 711, and 570cm 1 H 60MHz, CDCl3 2.09 3H, s , 4.6 5.0 5H, m , 5.75 6.0 3H, m , and 8.5 1H, br s . g. 65 5 Acetoxy D 2 2,2,2 trichloroethoxyearbonyl amino pent 3 E enamido penicillanic acidOxalyl chloride 0.07g was added to DMF 0.04g in dichloromethane 3ml at 200C under argon. The mixture was stirred for 15minutes in an ice bath, then cooled to 200C. 5 Acetoxy D 2 2,2,2 trichloroethoxycarbonylamino pent 3 enoic acid 0.20g in dichloromethane 3ml was added. The mixture was stirred for 15 minutes in, an ice bath, then cooled to 150C. 6 Aminopenicillanic acid triethylammonium salt 0.21g and triethylamine 0.07g in dichloromethane 3ml were added and the mixture was stirred at room temperature for 1.1h. The mixture was concentrated in vacuo, partitioned between water 15ml and ethyl acetate 15ml , acidified and separated.The aqueous phase was re extracted with ethyl acetate 15ml . The combined organic extracts were washed with water 15ml x 2 and brine 15ml , dried MgSO4 and concentrated in vacuo, to yield the crude title compound 0.33g, quantative .h. 6ss 5 Acetoxy D 2 aminopent 3 E enamido penicillanic acidThe title compound was obtained from 6p 5 Acetoxy D 2 2,2,2 trichloroethoxycarbonylamino pent 3 E enamido penicillanic acid by a procedure similar to that described in Example 2c O.llg, 52 9max KBr 3389, 2969, 1771, 1688, 1602, 1386, 1316 and 1242cm 1 SH 250MHz, D20 1.49 3H, s , 1.60 3H, s , 2.12 3H, s , 4.23 1H, s , 4.58 4.69 3H, m , 5.48 1H, d, J 3.8Hz , 5.55 1H, d, J 3.8Hz , 5.81 5.91 lH, m , and 6.14 6.24 1H, m . Mass spectrum ve ion thioglycerol MH 372 . Example 24 a. Methyl 3 bromo 2 methoxyiminopropanoate Methyl bromopyruvate 43.66g, 0.241mol and methoxyamine hydrochloride 20.15g, 0.241mol were dissolved in methanol 220ml and stirred for 4h at room temperature. After evaporation, the residue was taken up in ethyl acetate, washed with water and brine, dried and evaporated to give a yellow oil 45.0g, 90 . A pure sample was obtained after flash chromatography 6H 60MHz, CDC13 3.9 3H, s , 4.17 3H, s , and 4.21 and 4.38 2H, 2s .b. Methyl 3 dimethylphosphonyl 2 methoxyiminopropanoateMethyl 3 bromo 2 methoxyiminopropanoate 20. 00g, 95mmol and trimethylphosphite 40ml were refluxed for lh. The e excess trimethylphosphite was removed in vacuo, and the residue distilled to give, after a forerun of dimethyl methanephosphonate, the title compound as a colourless oil 19.45g, 86 , b.p.159 161 C 4.5mmHg 9max film 1720, 1270, 1210, 1170, 1040, 850 and 780cm 1 SH 250MHz, CDCl3 3.34 2H, d,J 23.5Hz , 3.75 6H, d, J 11.2Hz , 3.89 3H, 8 , and 4.13 3H, s , single isomer .c. Methyl 3 cyclohexylidene 2 methoxyiminopropanoateMethyl 3 dimethylphosphonyl 2 methoxyiminopropanoate 7.17g, 30mmol in THF 20ml was added dropwise to a stirred suspension of sodium hydride 50 in oil, 1.44g, 30mmol in THF 100ml . The mixture was stirred for 2h, then cyclohexanone 3.11ml, 30mmol in THF 15ml added dropwise. The mixture was stirred overnight, then diluted with ammonium chloride solution 150m1 , and extracted with ethyl acetate 3x50ml .The combined extracts were washed with brine, dried and evaporated. Flash chromatography on silica gel, using 0 5 ethyl acetate in hexane as eluant, gave the title compound as a colourless oil 2.31g, 36 max film 2930, 1730, 1430, 1200, 1150, 1050 and 760cm 1 oH 250MHz, CDCl3 1.5 2.4 10H, m , 3.85 3H, s , 4.05 3H, s , and 5.77 1H, s , single isomer .d. Methyl 2 amino 3 cyclohexylidenepropanoate Prepared as described in Example 12b 498 9max film 2930, 2850, 1735, 1440, 1430, 1200 and 1170cm 1 SH 60MHz, CDC13 , 1.4 2.4 12H, m , 3.7 3H, s , 4.3 1H, d, J 9Hz , and 5.1 1H, d, J 9Hz . e. Methyl 3 cyclohexylidene 2 2,2,2 trichloroethoxycarbonylamino propanoatePrepared as described in Example 12c quantitative dH 60MHz, CDCl3 1.4 1.8 6H, m , 2.0 2.5 4H, m , 3.75 3H, s , 4.75 2B, s , 5.0 5.3 2H, m , and 5.93 1H, br .f. 3 Cyclohexylidene 2 2,2,2 trichloroethoxycarbonylamino propanoic acidPrepared as described in Example 12d, using only one equivalent of base 56 , m.p. 139 1400C ethyl acetate cyclohexane 9max KBr 3334, 2937, 1706, 1526, 1292, 1240, 1052 and 723cm 1 H 250MHz, CD3 2CO 1.58 6H, m , 2.14 2H, m , 2.33 2H, m , 4.77 and 4.82 2H, ABq, J 12.2Hz , 5.03 1H, dd, J 9.1, 7.6Hz , 5.23 1H, d, J 9.1Hz , and 7.14 1H, br d, exchD20 . g. 6P D,L 3 Cyclohexylidene 2 2,2,2 trichlorethoxy carbonylamino propanamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 92 . h. 6ss 2 Amino 3 cyclohexylidenepropanamido penicillanic acidsDeprotection of 6p D,L 3 cyclohexylidene 2 2,2,2 trichloroethoxycarbonylamino propanamidozpenicillanic acid 1.6g, 2.9mmol was performed as described inExample 2c. Chromatography of the crude product onHP20SS, eluting with 6 7 THF in water, provided 6ss L 2 amino 3 cyclohexylidenepropanamido penicillanic acid 105mg, 10 Vmax KBr 2929, 2855, 1757, 1710, 1606, 1511 and 1322cm 1 H 250MHz, D2O 1.5 1.7 12H, m , 2.1 2.45 4H, m , 4.61 1H, s , 4.96 1H, d,J lO.OHz , 5.23 1H, d, J 10.0HZ 5.51 1H, d, J 4.1Hz , and 5.69 1H, d, J .1Hz followed by a mixture of D and L stereoisomers 163mg, 15 then 6p D 2 amino 3 cyclohexylidenepropanamido penicillanic acid 90mg, 88 9max KBr 2926, 1766, 1701, 1608, 1512, 1396 and 1325cm 1 dH 250MHz, D20 1.45 1.7 12H, m , 2.15 2.4 4H, m , 4.56 1H, s , 4.90 1H, d,J 10.0Hz , 5.19 1H, d, J 10.0Hz , 5.52 1H, d, J 4.0Hz , and 5.62 1H, d, J 4.0Hz .Example 25Methyl 2 hydroxyimino 4 methoxy 3 oxobutanoateSodium nitrite 11.64g in water 45ml was added dropwise over 0.5h to an ice bath cooled solution of methyl 4 methoxyacetoacetate 21.9g in glacial acetic acid 30m1 , below 200C. The mixture was stirred for a further 0.25h, then cooling was removed. After a further 0.25h the mixture was diluted with water and extracted with ethyl acetate 4x50ml . The combined organic extracts were washed with water 2x50ml , 1MNaHC03 solution 3x50ml and brine 2x50ml . The aqueous phases were back extracted with ethyl acetate.The organic phase was dried, concentrated and crystallised from ethyl acetate hexane 19.7g, 75 , m.p. 109 1120C Found C, 41.30 H, 4.99 N, 7.95 . C6H9NO5 requires C, 41.15 H, 5.18 N, 8.00 max KBr 3213, 1755, 1704, 1384, 1030 and 1007cm 1 sH 60MHz, CD3 2CO 3.38 3H, s , 3.84 3H, s , 4.54 2H, s , and 11.81 1H, s .Methyl 4 methoxy 2 methoxyimino 3 oxobutanoateDimethyl sulphate lOml in acetone 20ml was added dropwise over 0.25h to an ice bath cooled solution of methyl 2 hydroxyimino 4 methoxy 3 oxobutanoate 19.27g and potassium carbonate 15.20g in acetone 80ml . The cooling was removed and the mixture stirred at room temperature for 4.5h. Ethyl acetate 100ml and water 100ml were added to the partially concentrated solution. The aqueous phase was extracted again with ethyl acetate. The combined organic extracts were washed with water and brine, dried and concentrated in vacuo. Flash chromatography, eluting with 10 25 ethyl acetate hexane, yielded the title compound 10.66g, 51 9max film 1752, 1715, 1439, 1309, 1221 and 1049cm 1 SH 60MHz, CDC13 3.44 3H, s , 3.87 3H, s , 4.10 3H, s , and 4.54 2H, s .Methyl 4 methoxy 2 methoxyimino 3 methylenebutanoateMethyltriphenylphosphonium bromide 14.16g was added in portions to a suspension of potassium t butoxide 4.45g in THF 50ml at room temperature under argon. The mixture was heated at reflux for lh, cooled to room temperature, and methyl 4 methoxy 2 methoxyimino 3 oxobutanoate 5.lg in THF 35m1 added. The mixture was heated at 600C for 5 minutes, then cooled. Water 50m1 and ethyl acetate 50m1 were added, and the aqueous phase extracted again with ethyl acetate 50ml . The combined organic extracts were washed with water 2x50m1 , brine 2x50m1 , dried and concentrated in vacuo. Flash chromatography, eluting with 10 ethyl acetate hexane, yielded the title compound 2.35g, 47 9max film 1747, 1343, 1243, 1088 and 1041cm 1 6H 60MHz, CDCl3 3.35 3H, s , 3.80 3H, s , 3.87 3H, s , 4.0 4.2 2H, m , 5.2 5.3 1H, m , and 5.6 5.7 1H, m .Methyl 2 amino 4 methoxy 3 methylnenebutanoatePrepared as described in Example 12b 70 vmax film 2900 br , 1750, 1580 br , 1240 and 1100cm 1 6H 60MHz, CDCl3 3.30 3H, s , 3.78 3H, s , 4.05 2H, s , 4.59 1H, s , 5.3 5.6 2H, m , and 8.6 9.0 2H, br .Methyl 4 methoxy 3 methylene 2 2,2,2 trichloroethoxycarbonylamino butanoatePrepared as described in Example 12c 81 , m.p.50 52 C hexane vial KBr 3407, 1735, 1501, 1322, 1203 and 1089cm 1 OH 60MHz, CDCl3 3.32 3H, s , 3.77 3H, s , 4.01 2H, s , 4.76 2H, s , 4.97 1H, d,J 6.7Hz , 5.36 2H, s , and 6.1 1H, br . 4 Methoxy 3 methylene 2 2,2,2 trichloroethoxycarbonylamino butanoic acidPrepared as described in Example 12d 358 9max KBr 3390, 1744, 1714, 1699, 1514 and 1223cm 1 SH 60MHz, CD3 2CO 3.29 3H, s , 4.05 H, s , 4.79 2H, s , 4.91 1H, d, J 8.7Hz , 5.2 5.5 2H, m , 7.0 1H, br , and 8.45 1H, br .6ss D,L 4 Methoxy 3 methylene 2 2,2,2 trichloroethoxycarbonylamino butanamido penicillanaic acidPrepared as described in Example 2b, but not converted to the sodium salt 88 . 6p D,L 2 Amino 4 methoxy 3 methylenebutanamido penicillanic acidDeprotection of 6ss D,L 4 methoxy 3 methylene 2 2,2,2trichloroethoxycarbonylamino butanamido penicillanic acid 0.71g as described in Example 2c gave the title compound, isolated after chromatography on HP20SS, as a white freeze dried solid O.llg, 23 9max KBr 3220, 1775, 1689, 1610, 1524, 1391, 1316 and 1095cm1 oH 250MHz, D20 1.54 and 1.55 together 3H, 2s , 1.63 and 1.64 together 3H, 2s , 3.39 and 3.40 together 3H, 2s , 4.13 and 4.14 together 2H, 2s , 4.27 and 4.28 together 1H, 2s , 4.78 and 4.79 together 1H, 2s , and 5.5 5.7 4H, m . Example 26 a. Methyl 2 methoxyimino 4 methylpent 3 enoatePrepared as described in Example 24c, using an excess of acetone, to give, after chromatography, the title compound 24 Found M , 171.0893. C8Hl3NO3 requiresM, 171.0895 9max film 1730, 1440, 1300, 1200, 1150, 1060 and 1040cm 1 H 60MHz, CDCl3 1.62 3H, s , 1.9 3H, s , 3.84 3H, s , 4.02 3H, s , and 5.9 1H, m .b. Methyl 2 amino 4 methylpent 3 enoatePrepared as described in Example 12b dH 60MHz,CDCl3 1.75 6H, s , 2.1 2H, s , 3.72 3H, s , 4.3 1H, d, J 9Hz , and 5.2 1H, m .c. Methyl 4 methyl 2 2,2,2 trichloroethoxycarbonyl amino pent 3 enoatePrepared as described in Example 12c quantitative H 60MHz, CDCl3 1.75 3H, s , 1.80 3H, s , 3.7 3H, s , 4.7 2H, s , 5.0 2H, m , and 6.0 1H, br .d. 4 Methyl 2 2,2,2 trichloroethoxycarbonylamino pent 3 enoic acidPrepared as described in Example 12d, using only one equivalent of base 34 over three steps , m.p. 199200 C ethyl acetate cyclohexane max KBr 3297, 1733, 1701, 1541, 1288, 1250 and 721cm 1 6H 250MHz, CD3 2CO 1.77 3H, d, J 1.1Hz , 1.82 3H, d, J 1.1Hz , 4.78 and 4.82 2H, ABq, J 12.2Hz , 4.97 1H, dd, J 9.1, 7.7Hz , 5.28 1H, dt, J 9.1, 1.1Hz , and 7.15 1H, br d . e. 6H ED,L 4 Methyl 2 2,2,2 trichloroethoxycarbonyl amino pent 3 enamido penicillanic acidPrepared as described in Example 2b, but not converted to the sodium salt 87 .f. 6ss 2 Amino 4 methylpent 3 enamido penicillanic acidsDeprotection of 6ss D,L 4 methyl 2 2,2,2 trichloroethoxycarbonylamino pent 3 enamido penicillanic acid 1.70g, 3.4mmol was performed as described in Example 2c. Chromatography of the crude product on HP20SS, eluting with 2 THF in water, provided 6P L 2 amino 4methylpent 3 enamido penicillanic acid 38mg, 3.48 max KBr 2972, 1774, 1689, 1607, 1517, 1389 and 1315cm 1 dH 250MHz, D20 1.56 3H, s , 1.62 3H, s , 1.89 6H, s , 4.31 1H, s , 4.90 1H, d, J lO.OHz , 5.30 1H, m , 5.49 1H, d, J 4.0Hz , and 5.65 1H, d, J 4.0Hz followed by a mixture of D and L stereoisomers 276mg, 258 then 6ss D 2 amino 4 methylpent 3 enamido penicillanic acid 77mg, 7 max KBr 2970, 1774, 1690, 1604, 1517, 1390 and 1316cm 1 dH 250MHz, D20 1.55 3H, s , 1.63 3H, s , 1.88 6H, d, J l.OHz , 4.29 1H, s , 4.90 1H, d, J 10.0Hz , 5.30 1H, m , 5.52 1H, d, J 3.9Hz , and 5.60 1H, d, J 3.9Hz . Example 27The following Table gives the Absorption Index Ethat is the ratio of urine recoveries from oral p.o and subcutaneous s.c administration following administration of the compounds of the invention to mice 5 mice per group at a dose of 50mg kg.Comparative figures for Amoxycillin are also given.Table 1 Absorption Index in the Mouse Recovery mean Compound of p.o 8.C Absorption Example Index p.o s.c 1 79 98 4 D stereoisomer 21 86 0.3 5 D stereoisomer 37 87 0.4 6 44 103 0.4 9 D stereoisomer 34 116 0.3 11 D stereoisomer 48 63 0.76 13 D stereoisomer 45 61 0.74 14 D stereoisomer 11 18 0.6Amoxycillin 23 56 0.4 Example 28The following Table gives mean Squirrel Monkey Plasma levels in g ml following oral administration of 25mg kg of a compound of the invention to the number of animals indicated.Comparative figures for Amoxycillin, administered at the same dose, are also given.Table 2 Squirrel Monkey Plasma Levels.Compound of Time in Minutes Area underExample No. 15 30 60 120 240 360 the curve No. of g.h ml animals 1 4.0 14.7 32.7 15.7 2.4 0.8 59.7 3 5 D stereoisomer 20.7 28.8 24.3 16.8 2.4 1.4 63.0 3 6 8.7 16.4 20.0 13.0 2.2 0.9 46.5 6Amoxycillin 4.8 9.7 12.6 6.7 1.1 0.3 26.2 6 Example 29The following Table gives Minimum InhibitoryConcentration MIC values for some of the compounds of the invention against S.pyogenes CN 10 and E.coli NCTC 10418. The E. coli was grown in tryptone soya broth and the S. pyogenes was grown in Todd Hewitt broth.The microorganisms were grown for 24hours and 1p1 samples were then inoculated on to agar plates comprising 5 v v live horse blood agar to which had been added the compounds of the invention at a series of two fold dilutions. After a further 24 hours, theMIC values were determined by visual inspection.Table 3 MIC DataCompound of S. pyogenes E. coli NCTC Example CN 10 10418 1 0.03 8 4 D stereoisomer 0.03 8 5 D stereoisomer 0.03 2 6 0.03 2 7 0.25 32 8 2 9 D stereoisomer 0.03 2 10 D stereoisomer 0.06 2 11 D stereoisomer 0.06 8 12 D stereoisomer 0.06 s 2 13 D stereoisomer 0.06 4 14 D stereoisomer 0.06 16 15 D stereoisomer 0.06 16 16 0.06 16 Table 3 Cont d MIC DataCompound of S. pyogenes E. coli NCTC Example CN 10 10418 17 D stereoisomer 0.06 4 18 D stereoisomer 0.06 16 19 0.03 16 20 0.06 32 21 D stereoisomer 0.06 4 22 0.12 8 23 0.12 32 Example 30The following Table gives CD50 values obtained after infecting groups of mice with a lethal inoculum of various bacteria and treating the mice with the compounds quoted. The CD50 value then represents the amount of compound necessary to protect 50 of the animals.Table 4. CD50 Data Total CD50 mg kg Organism Route Compound of Compound of Example 5 Example 6 D stereoisomer S.aureus Smith p.o. 0.05 0.08 s.c. 0.08 0.15 p.o. 0.25 0.10 s.c. 0.09 0.15 MIC gg ml 0.06 0.12 S.agalactiae p.o. 0.6 3.8 2798 s.c. 0.12 1.1 p.o. 0.9 3.6 s.c. 0.5 1.5 MIC g ml 0.06 0.25 E.coli 96 R p.o. 40 32 s.c. 22 6 p.o. 40 40 s.c. 40 28 MIC g ml 2 4